BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

GenCore version 5.1.6

OM nucleic - nucleic search, using sw model

Run on: January 8, 2004, 17:18:44 ; Search time 535 Seconds
(without alignments)
10313.367 Million cell updates/sec

Title: US-10-006-485A-139
Perfect score: 2044
Sequence: 1 gggggcgggtgcctggagca.....aaaaaaaaaaaaaaaaaga 2044

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*
25: /SIDS1/gcgdata/geneseq/geneseqn-embl/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	2044	100.0	2044	22	AAF54299	DNA encoding prote
	2	2044	100.0	2044	24	ABL95659	Human angiogenesis
	3	2044	100.0	2044	24	ABL88170	Human PRO1412 cDNA
	4	2041	99.9	2043	21	AAA37063	Human PRO1412 (UNQ
	5	2032	99.4	2043	24	ABK33622	cDNA encoding huma
	6	1998.2	97.8	2011	21	AAZ98132	Human signal pepti
	7	1935.2	94.7	2498	24	ABX34032	Human cancer suppr
	8	1889.6	92.4	1930	22	AAF25176	Nucleotide sequenc
	9	1356.8	66.4	1556	22	AAF94473	Human hydrophobic
	10	1284.6	62.8	1490	20	AAX97964	Human secreted pro
	11	1155.8	56.5	1188	24	AAS97018	DNA encoding human
	12	1016	49.7	1016	24	AAS62589	cDNA sequence #376
	13	970.4	47.5	5920	22	AAK85139	Human immune/haema
	14	929.8	45.5	933	22	AAF25166	Nucleotide sequenc
c	15	770.4	37.7	6197	24	ABA00061	CADHP-8 coding seq
	16	581	28.4	581	24	ABS51586	Human cDNA encodin
	17	488.2	23.9	4530	23	AAS68062	DNA encoding novel
	18	486.4	23.8	3210	25	ABT32158	Human neuroblastom
c	19	441.2	21.6	514	24	ABT11068	Human breast cance
	20	432.2	21.1	1778	22	AAK84200	Human immune/haema
	21	423	20.7	431	21	AAC74829	Human ORFX ORF384
	22	422.4	20.7	504	22	AAF94463	Human hydrophobic
	23	282.6	13.8	300	16	AAT26043	Human gene signatu
	24	218.2	10.7	929	22	AAI94126	Human neuroblastom
	25	54.6	2.7	88421	24	AAL40781	88421nt genomic DN
	26	53.2	2.6	1321	21	AAF16332	Human prostate can
	27	52.6	2.6	2329	22	AAF97884	Human secreted pro
	28	52.4	2.6	694	22	AAD06200	Human uteroglobin-
	29	52.4	2.6	2001	25	ABV72464	Nucleotide sequenc
	30	52.2	2.6	2300	25	ABX63220	Human cDNA #220 di
c	31	51.4	2.5	2797	25	ABT19785	Aspergillus fumiga
c	32	51.4	2.5	3048	25	ABT17971	Aspergillus fumiga
	33	51.2	2.5	2031	21	AAC55226	Human secreted pro
	34	51.2	2.5	2031	21	AAC55227	Human secreted pro
	35	51.2	2.5	3353	24	ABQ54155	Human ovarian anti
	36	51.2	2.5	3354	21	AAC55197	Human secreted pro
	37	51	2.5	51	21	AAA76891	Human clone cg3952
	38	51	2.5	385	22	AAI84859	Human polynucleoti
	39	51	2.5	426	22	AAI88632	Human polynucleoti
	40	51	2.5	5440	25	ACC44838	Mouse LTBP-4 long
	41	50.8	2.5	811	23	ABK72047	Human cDNA encodin
	42	50.8	2.5	811	24	ABK91639	cDNA encoding nove
	43	50.8	2.5	892	21	AAC98035	Human colon cancer
	44	50.8	2.5	1154	22	AAS29109	cDNA encoding for
	45	50.8	2.5	1154	24	ABS68249	cDNA encoding huma

ALIGNMENTS

RESULT 1
AAF54299
ID AAF54299 standard; DNA; 2044 BP.
XX
AC AAF54299;
XX
DT 02-APR-2001 (first entry)
XX
DE DNA encoding protein of the invention #42.
XX
KW Secreted; transmembrane; gene therapy; ss.
XX
OS Unidentified.
XX
PN WO200078961-A1.
XX
PD 28-DEC-2000.
XX
PF 18-FEB-2000; 2000WO-US04342.
XX
PR 23-JUN-1999; 99US-0141037.
PR 20-JUL-1999; 99US-0144758.
PR 26-JUL-1999; 99US-0145698.
PR 01-SEP-1999; 99WO-US20111.
PR 29-OCT-1999; 99US-0162506.
PR 30-NOV-1999; 99WO-US28313.
PR 02-DEC-1999; 99WO-US28551.
PR 16-DEC-1999; 99WO-US30095.
PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
XX

PA (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D;
PI Watanabe CK, Williams PM, Wood WI;
XX
DR WPI; 2001-071395/08.
XX
PT Secreted and transmembrane proteins and nucleic acids designated PRO,
PT useful as hybridization probes, in chromosome and gene mapping and gene
PT therapy -
XX
PS Claim 2; Fig 83; 787pp; English.
XX
CC The present invention relates to secreted and transmembrane proteins.
CC These proteins and the DNA encoding them may be used as hybridization
CC probes, in chromosome and gene mapping and in the generation of
CC anti-sense RNA and DNA. They may also be used used to generate either
CC transgenic animals or knockout animals which are in turn useful for
CC development and screening of therapeutically useful reagents.
CC The nucleic acids may also be used in gene therapy.
XX
SQ Sequence 2044 BP; 394 A; 678 C; 576 G; 396 T; 0 other;

Query Match 100.0%; Score 2044; DB 22; Length 2044;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2044; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60

Qy         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120

Qy        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180

Qy        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240

Qy        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300

Qy        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360

Qy        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420

Qy        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480

Qy        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540

Qy        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600

Qy        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660

Qy        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720

Qy        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780

Qy        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840

Qy        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900

Qy        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960

Qy        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020

Qy       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080

Qy       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140

Qy       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200

Qy       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260

Qy       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320

Qy       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380

Qy       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440

Qy       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500

Qy       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560

Qy       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620

Qy       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680

Qy       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740

Qy       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800

Qy       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860

Qy       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920

Qy       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980

Qy       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040

Qy       2041 AAGA 2044
                ||||
Db       2041 AAGA 2044
```

RESULT 2
ABL95659
ID ABL95659 standard; cDNA; 2044 BP.
XX
AC ABL95659;
XX
DT 19-JUL-2002 (first entry)
XX
DE Human angiogenesis related cDNA PRO1412 SEQ ID NO: 197.
XX
KW Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW antiarteriosclerotic; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200208284-A2.
XX
PD 31-JAN-2002.
XX
PF 09-JUL-2001; 2001WO-US21735.
XX
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220664P.
PR 28-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222695P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 15-SEP-2000; 2000US-000000P.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 28-JUN-2001; 2001WO-US00000.
XX
PA (GETH) GENENTECH INC.
PA (BAKE/) BAKER K P.
PA (FERR/) FERRARA N.
PA (GERB/) GERBER H.
PA (GERR/) GERRITSEN M E.
PA (GODD/) GODDARD A.
PA (GODO/) GODOWSKI P J.
PA (GURN/) GURNEY A L.
PA (HILL/) HILLAN K J.
PA (MARS/) MARSTERS S A.
PA (PANJ/) PAN J.
PA (PAON/) PAONI N F.
PA (STEP/) STEPHAN J F.
PA (WATA/) WATANABE C K.
PA (WILL/) WILLIAMS P M.
PA (WOOD/) WOOD W I.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-171999/22.
DR P-PSDB; ABB95521.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 1; Fig 197; 567pp; English.
XX
CC The present invention provides the protein and coding sequences of human
CC PRO proteins. These are useful for treating or diagnosing a
CC cardiovascular, endothelial or angiogenic disorder, including cardiac
CC hypertrophy, trauma, cancer, age-related macular degeneration,
CC atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC healing. The present sequence is a coding sequence of the invention.
XX
SQ Sequence 2044 BP; 394 A; 678 C; 576 G; 396 T; 0 other;

```
  Query Match             100.0%;  Score 2044;  DB 24;  Length 2044;
  Best Local Similarity   100.0%;  Pred. No. 0;
  Matches 2044;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60

Qy         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120

Qy        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180

Qy        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
```

```
Qy       241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
Db       241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300

Qy       301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
Db       301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360

Qy       361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
Db       361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420

Qy       421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
Db       421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480

Qy       481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
Db       481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540

Qy       541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
Db       541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600

Qy       601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
Db       601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660

Qy       661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
Db       661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720

Qy       721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780
Db       721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780

Qy       781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
Db       781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840

Qy       841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
Db       841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900

Qy       901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
Db       901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960

Qy       961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
Db       961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020

Qy      1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
Db      1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080

Qy      1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
Db      1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140

Qy      1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
Db      1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200

Qy      1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
Db      1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260

Qy      1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
Db      1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320

Qy      1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
Db      1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380

Qy      1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
Db      1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440

Qy      1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
Db      1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500

Qy      1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
Db      1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560

Qy      1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
Db      1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620

Qy      1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
Db      1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680

Qy      1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
Db      1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740

Qy      1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
Db      1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800

Qy      1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
Db      1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860

Qy      1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
Db      1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920

Qy      1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
Db      1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980

Qy      1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040
Db      1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040

Qy      2041 AAGA 2044
Db      2041 AAGA 2044
```

RESULT 3
ABL88170
ID ABL88170 standard; cDNA; 2044 BP.
XX
AC ABL88170;
XX
DT 16-MAY-2002 (first entry)
XX
DE Human PRO1412 cDNA sequence SEQ ID NO:197.
XX
KW Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW age-related macular degeneration; arterial restenosis; angina;
KW rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW wound healing; chromosome mapping; gene mapping; gene; ss.
XX
OS Homo sapiens.
XX

PN WO200200690-A2.
XX
PD 03-JAN-2002.
XX
PF 20-JUN-2001; 2001WO-US19692.
XX
PR 23-JUN-2000; 2000US-213637P.
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220664P.
PR 28-JUL-2000; 2000WO-US20710.
PR 02-AUG-2000; 2000US-222695P.
PR 17-AUG-2000; 2000US-0643657.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 07-SEP-2000; 2000US-230978P.
PR 18-SEP-2000; 2000US-0664610.
PR 18-SEP-2000; 2000US-0665350.
PR 24-OCT-2000; 2000US-242922P.
PR 08-NOV-2000; 2000US-0709238.
PR 08-NOV-2000; 2000WO-US30952.
PR 10-NOV-2000; 2000WO-US30873.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 22-JAN-2001; 2001US-0767609.
PR 28-FEB-2001; 2001US-0796498.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-MAR-2001; 2001WO-US06666.
PR 09-MAR-2001; 2001US-0802706.
PR 14-MAR-2001; 2001US-0808689.
PR 22-MAR-2001; 2001US-0816744.
PR 05-APR-2001; 2001US-0828366.
PR 10-MAY-2001; 2001US-0854208.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-090516/12.
DR P-PSDB; ABB84915.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 2; Fig 197; 565pp; English.
XX
CC ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,
CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC degeneration, atherosclerosis, hypertension, arterial restenosis,
CC rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC carcinoma) and wound healing. The PRO polynucleotides have applications
CC in molecular biology, including use as hybridisation probes, and in
CC chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC probes used in the exemplification of the present invention.
XX
SQ Sequence 2044 BP; 394 A; 678 C; 576 G; 396 T; 0 other;

Query Match 100.0%; Score 2044; DB 24; Length 2044;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2044; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60

Qy         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120

Qy        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180

Qy        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240

Qy        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300

Qy        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360

Qy        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420

Qy        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480

Qy        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540

Qy        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600

Qy        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660

Qy        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720

Qy        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCCTCATCCTGCTC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCCTCATCCTGCTC 780

Qy        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840

Qy        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900

Qy        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960

Qy        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
```

```
Qy       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080

Qy       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140

Qy       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200

Qy       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260

Qy       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320

Qy       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380

Qy       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440

Qy       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500

Qy       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560

Qy       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620

Qy       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680

Qy       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740

Qy       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800

Qy       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860

Qy       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920

Qy       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980

Qy       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040

Qy       2041 AAGA 2044
             ||||
Db       2041 AAGA 2044
```

```
RESULT 4
AAA37063
ID   AAA37063 standard; cDNA; 2043 BP.
XX
AC   AAA37063;
XX
DT   08-AUG-2000  (first entry)
XX
DE   Human PRO1412 (UNQ730) cDNA sequence SEQ ID NO:139.
XX
KW   Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW   transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
KW   ss.
XX
OS   Homo sapiens.
XX
PN   WO200012708-A2.
XX
PD   09-MAR-2000.
XX
PF   01-SEP-1999;   99WO-US20111.
XX
PR   01-SEP-1998;   98US-0098716.
PR   01-SEP-1998;   98US-0098749.
PR   01-SEP-1998;   98US-0098750.
PR   02-SEP-1998;   98US-0098803.
PR   02-SEP-1998;   98US-0098821.
PR   02-SEP-1998;   98US-0098843.
PR   09-SEP-1998;   98US-0099536.
PR   09-SEP-1998;   98US-0099596.
PR   09-SEP-1998;   98US-0099598.
PR   09-SEP-1998;   98US-0099602.
PR   09-SEP-1998;   98US-0099642.
PR   10-SEP-1998;   98US-0099741.
PR   10-SEP-1998;   98US-0099754.
PR   10-SEP-1998;   98US-0099763.
PR   10-SEP-1998;   98US-0099792.
PR   10-SEP-1998;   98US-0099808.
PR   10-SEP-1998;   98US-0099812.
PR   10-SEP-1998;   98US-0099815.
PR   10-SEP-1998;   98US-0099816.
PR   15-SEP-1998;   98US-0100385.
PR   15-SEP-1998;   98US-0100388.
PR   15-SEP-1998;   98US-0100390.
PR   16-SEP-1998;   98US-0100584.
PR   16-SEP-1998;   98US-0100627.
PR   16-SEP-1998;   98US-0100661.
PR   16-SEP-1998;   98US-0100662.
PR   16-SEP-1998;   98US-0100664.
PR   17-SEP-1998;   98US-0100683.
PR   17-SEP-1998;   98US-0100684.
PR   17-SEP-1998;   98US-0100710.
PR   17-SEP-1998;   98US-0100711.
PR   17-SEP-1998;   98US-0100919.
PR   17-SEP-1998;   98US-0100930.
PR   18-SEP-1998;   98US-0100848.
PR   18-SEP-1998;   98US-0100849.
PR   18-SEP-1998;   98US-0101014.
PR   18-SEP-1998;   98US-0101068.
PR   18-SEP-1998;   98US-0101071.
PR   22-SEP-1998;   98US-0101279.
PR   23-SEP-1998;   98US-0101471.
PR   23-SEP-1998;   98US-0101472.
PR   23-SEP-1998;   98US-0101474.
PR   23-SEP-1998;   98US-0101475.
PR   23-SEP-1998;   98US-0101476.
PR   23-SEP-1998;   98US-0101477.
PR   23-SEP-1998;   98US-0101479.
PR   24-SEP-1998;   98US-0101738.
PR   24-SEP-1998;   98US-0101741.
PR   24-SEP-1998;   98US-0101743.
PR   24-SEP-1998;   98US-0101915.
PR   24-SEP-1998;   98US-0101916.
```

PR 29-SEP-1998; 98US-0102207.
PR 29-SEP-1998; 98US-0102240.
PR 29-SEP-1998; 98US-0102307.
PR 29-SEP-1998; 98US-0102330.
PR 29-SEP-1998; 98US-0102331.
PR 30-SEP-1998; 98US-0102484.
PR 30-SEP-1998; 98US-0102487.
PR 30-SEP-1998; 98US-0102570.
PR 30-SEP-1998; 98US-0102571.
PR 01-OCT-1998; 98US-0102684.
PR 01-OCT-1998; 98US-0102687.
PR 02-OCT-1998; 98US-0102965.
PR 06-OCT-1998; 98US-0103258.
PR 06-OCT-1998; 98US-0103449.
PR 07-OCT-1998; 98US-0103314.
PR 07-OCT-1998; 98US-0103315.
PR 07-OCT-1998; 98US-0103328.
PR 07-OCT-1998; 98US-0103395.
PR 07-OCT-1998; 98US-0103396.
PR 07-OCT-1998; 98US-0103401.
PR 08-OCT-1998; 98US-0103633.
PR 08-OCT-1998; 98US-0103678.
PR 08-OCT-1998; 98US-0103679.
PR 08-OCT-1998; 98US-0103711.
PR 14-OCT-1998; 98US-0104257.
PR 20-OCT-1998; 98US-0104987.
PR 20-OCT-1998; 98US-0105000.
PR 20-OCT-1998; 98US-0105002.
PR 21-OCT-1998; 98US-0105104.
PR 22-OCT-1998; 98US-0105169.
PR 22-OCT-1998; 98US-0105266.
PR 26-OCT-1998; 98US-0105693.
PR 26-OCT-1998; 98US-0105694.
PR 27-OCT-1998; 98US-0105807.
PR 27-OCT-1998; 98US-0105881.
PR 27-OCT-1998; 98US-0105882.
PR 27-OCT-1998; 98US-0106062.
PR 28-OCT-1998; 98US-0106023.
PR 28-OCT-1998; 98US-0106029.
PR 28-OCT-1998; 98US-0106030.
PR 28-OCT-1998; 98US-0106032.
PR 28-OCT-1998; 98US-0106033.
PR 28-OCT-1998; 98US-0106178.
PR 29-OCT-1998; 98US-0106248.
PR 29-OCT-1998; 98US-0106384.
PR 29-OCT-1998; 98US-0108500.
PR 30-OCT-1998; 98US-0106464.
PR 03-NOV-1998; 98US-0106856.
PR 03-NOV-1998; 98US-0106902.
PR 03-NOV-1998; 98US-0106905.
PR 03-NOV-1998; 98US-0106919.
PR 03-NOV-1998; 98US-0106932.
PR 03-NOV-1998; 98US-0106934.
PR 10-NOV-1998; 98US-0107783.
PR 17-NOV-1998; 98US-0108775.
PR 17-NOV-1998; 98US-0108779.
PR 17-NOV-1998; 98US-0108787.
PR 17-NOV-1998; 98US-0108788.
PR 17-NOV-1998; 98US-0108801.
PR 17-NOV-1998; 98US-0108802.
PR 17-NOV-1998; 98US-0108806.
PR 17-NOV-1998; 98US-0108807.
PR 17-NOV-1998; 98US-0108867.
PR 17-NOV-1998; 98US-0108925.
PR 18-NOV-1998; 98US-0108848.
PR 18-NOV-1998; 98US-0108849.
PR 18-NOV-1998; 98US-0108850.
PR 18-NOV-1998; 98US-0108851.
PR 18-NOV-1998; 98US-0108852.
PR 18-NOV-1998; 98US-0108858.
PR 18-NOV-1998; 98US-0108904.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
XX
DR WPI; 2000-237871/20.
DR P-PSDB; AAY99381.
XX
PT New mammalian DNA sequences encoding transmembrane, receptor or
PT secreted PRO polypeptides, useful for screening of potential peptide or
PT small molecule inhibitors of the relevant receptor/ligand interactions
XX
PS Claim 2; Fig 83; 773pp; English.
XX
CC AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The
CC transmembrane and receptor PRO proteins can be used for screening of
CC potential peptide or small molecule inhibitors of the relevant
CC receptor/ligand interactions. The polypeptides and nucleotide sequences
CC encoding then have various industrial applications, including uses as
CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
CC PCR primers and hybridisation probes used in the isolation of the PRO
CC polypeptides from the present invention.
XX
SQ Sequence 2043 BP; 393 A; 678 C; 576 G; 396 T; 0 other;

Query Match 99.9%; Score 2041; DB 21; Length 2043;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2041; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60

Qy         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120

Qy        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180

Qy        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240

Qy        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300

Qy        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360

Qy        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420

Qy        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480

Qy        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540

Qy        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600

Qy        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660

Qy        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
```

```
Db        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
Qy        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780
Db        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780
Qy        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
Db        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
Qy        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
Db        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
Qy        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
Db        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
Qy        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
Db        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
Qy       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
Db       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
Qy       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
Db       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
Qy       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
Db       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
Qy       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
Db       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
Qy       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
Db       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
Qy       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
Db       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
Qy       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
Db       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
Qy       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
Db       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
Qy       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
Db       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
Qy       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
Db       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
Qy       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
Db       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
Qy       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
Db       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
Qy       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
Db       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
Qy       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
Db       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
Qy       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
Db       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
Qy       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
Db       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
Qy       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040
Db       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040
Qy       2041 A 2041
Db       2041 A 2041
```

RESULT 5
ABK33622
ID ABK33622 standard; cDNA; 2043 BP.
XX
AC ABK33622;
XX
DT 08-MAY-2002 (first entry)
XX
DE cDNA encoding human PRO protein, Seq ID No 173.
XX
KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200208288-A2.
XX
PD 31-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-US21066.
XX
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220585P.
PR 25-JUL-2000; 2000US-220605P.
PR 25-JUL-2000; 2000US-220607P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220638P.
PR 25-JUL-2000; 2000US-220664P.
PR 25-JUL-2000; 2000US-220666P.
PR 26-JUL-2000; 2000US-220893P.
PR 28-JUL-2000; 2000WO-US20710.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 15-SEP-2000; 2000US-000000P.
PR 10-NOV-2000; 2000WO-US30873.
PR 28-NOV-2000; 2000US-253646P.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001WO-US17092.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX

DR WPI; 2002-172001/22.
DR P-PSDB; AAU83678.
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumours
PT such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT tumour or liver tumour -
XX
PS Claim 2; Figure 173; 359pp; English.
XX
CC The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. ABK33536-ABK33657 represent human
CC PRO protein coding sequences of the invention.
XX
SQ Sequence 2043 BP; 394 A; 678 C; 575 G; 396 T; 0 other;

Query Match 99.4%; Score 2032; DB 24; Length 2043;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2043; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

```
Qy          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60

Qy         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120

Qy        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180

Qy        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240

Qy        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300

Qy        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360

Qy        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420

Qy        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480

Qy        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540

Qy        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600

Qy        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660

Qy        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720

Qy        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780

Qy        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840

Qy        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900

Qy        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960

Qy        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020

Qy       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080

Qy       1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
              |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1081 AGCT-GGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1139

Qy       1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1140 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1199

Qy       1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1200 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1259

Qy       1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1260 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1319

Qy       1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1320 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1379

Qy       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1380 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1439

Qy       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1440 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1499

Qy       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1500 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1559

Qy       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1560 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1619

Qy       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1620 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1679

Qy       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1680 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1739

Qy       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1740 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1799

Qy       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1800 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1859

Qy       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1860 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1919

Qy       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1920 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1979

Qy       1981 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2040
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1980 GGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 2039

Qy       2041 AAGA 2044
                ||||
Db       2040 AAGA 2043
```

RESULT 6
AAZ98132
ID AAZ98132 standard; cDNA; 2011 BP.
XX
AC AAZ98132;
XX
DT 11-MAY-2000 (first entry)
XX
DE Human signal peptide containing protein HSPP-24 cDNA SEQ ID NO:158.
XX
KW Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;
KW antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW reproductive disorder; developmental disorder; arteriosclerosis;
KW cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW Parkinson's disease; Huntington's diseases; ovulatory defect;
KW muscular dystrophy; ss.
XX
OS Homo sapiens.
XX
PN WO200000610-A2.
XX
PD 06-JAN-2000.
XX
PF 25-JUN-1999; 99WO-US14484.
XX
PR 26-JUN-1998; 98US-0090762.
PR 31-JUL-1998; 98US-0094983.
PR 01-OCT-1998; 98US-0102686.
PR 11-DEC-1998; 98US-0112129.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Lal P, Tang YT, Gorgone GA, Corley NC, Guegler KJ, Baughn MR;
PI Akerblom IE, Au-Young J, Yue H, Patterson C, Reddy R, Hillman JL;
PI Bandman O;
XX
DR WPI; 2000-160673/14.
DR P-PSDB; AAY87247.
XX
PT New human signal peptide-containing proteins useful in treatment,
PT prevention and diagnosis of e.g. cancer, inflammation and
PT cardiovascular disease -
XX
PS Claim 9; Page 266; 327pp; English.
XX
CC AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
CC anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC neuroprotective, cardiovascular and antiasthmatic activities, and can
CC be used in gene therapy. HSPPs can be used to treat or prevent disorders
CC associated with decreased activity or function of HSPP. Antagonists of
CC HSPP are used to treat or prevent disorders associated with increased
CC activity or function of HSPP. Such diseases include cell proliferation
CC (including cancer), inflammation, cardiovascular, neurological,
CC reproductive or developmental disorders, (e.g. arteriosclerosis,
CC cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC asthma, Crohn's disease, microbial or other infections, congestive or
CC ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
CC nucleic acids can be used for the recombinant production of HSPP, for
CC detecting HSPP in standard hybridisation and amplification assays (for
CC diagnosis and monitoring), in gene therapy, as antisense,
CC triplex-forming or ribozyme therapeutics, for detecting related sequences
CC or genetic variations, and for chromosomal mapping. HSPP are also used to
CC raise specific antibodies (Ab) and to screen for agonists and
CC antagonists (potential therapeutic agents). Ab are used to diagnose, or
CC monitor, HSPP-related diseases (in usual immunoassays), as therapeutic
CC antagonists, in competitive drug screens, and for purification of HSPP
CC from natural sources.
XX
SQ Sequence 2011 BP; 370 A; 678 C; 570 G; 393 T; 0 other;

Query Match 97.8%; Score 1998.2; DB 21; Length 2011;
Best Local Similarity 99.6%; Pred. No. 0;
Matches 2003; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

```
Qy         15 GGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTCAGTCGCGGGAGGCT 74
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTCAGTCGCGGGAGGCT 60

Qy         75 TCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTCCTCTGCGCGTCCGA 134
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 TCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTCCTCTGCGCGTCCGA 120

Qy        135 CGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGCTGGGGATCCCTGCT 194
              |||||||||||||||||||||||||| ||||||||||||||||||||||||||||||||||||
Db        121 CGGCGACATGGGCGTCCCCACGGCCCCGGAGGCCGGCAGCTGGCGCTGGGGATCCCTGCT 180

Qy        195 CTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTCAAGGTCGCCACGCC 254
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 CTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTCAAGGTCGCCACGCC 240

Qy        255 GTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACCTGCAGGCTCTTGGG 314
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 GTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACCTGCAGGCTCTTGGG 300

Qy        315 CCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTACCGCAGCTCGAGGGG 374
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 CCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTACCGCAGCTCGAGGGG 360

Qy        375 CGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACGTTCCAGGACCTTCA 434
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACGTTCCAGGACCTTCA 420

Qy        435 CCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTGGCTCAGCGCCACGG 494
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 CCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTGGCTCAGCGCCACGG 480

Qy        495 GCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATGCGCAACCTGACCCT 554
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 GCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATGCGCAACCTGACCCT 540

Qy        555 GCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCACCACCACTCGGAGCA 614
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCACCACCACTCGGAGCA 600
```

```
Qy       615 CAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGATGCACCATCCAACTG 674
Db       601 CAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGATGCACCATCCAACTG 660

Qy       675 TGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCTGCAGCCCTGGCTAC 734
Db       661 TGTGGTGTACCCATCCTCCTCCCAGGAGAGTGAAAACATCACGGCTGCAGCCCTGGCTAC 720

Qy       735 GGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTCCTGGTCTACAAGCA 794
Db       721 GGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTCCTGGTCTACAAGCA 780

Qy       795 AAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATGGACAGCAACATTCA 854
Db       781 AAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATGGACAGCAACATTCA 840

Qy       855 AGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGGATACCCGAGGCCAA 914
Db       841 AGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGGATACCCGAGGCCAA 900

Qy       915 AGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAGTCTGGGCGGCATCT 974
Db       901 AGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAGTCTGGGCGGCATCT 960

Qy       975 GCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATC 1034
Db       961 GCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATC 1020

Qy      1035 CCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGT 1094
Db      1021 CCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGT 1080

Qy      1095 GGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGG 1154
Db      1081 GGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGG 1140

Qy      1155 CCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATC 1214
Db      1141 CCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATC 1200

Qy      1215 CCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCC 1274
Db      1201 CCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCC 1260

Qy      1275 CCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCT 1334
Db      1261 CCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCT 1320

Qy      1335 ACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTC 1394
Db      1321 ACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTC 1380

Qy      1395 TCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGG 1454
Db      1381 TCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGG 1440

Qy      1455 CCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCT 1514
Db      1441 CCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCT 1500

Qy      1515 TGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTG 1574
Db      1501 TGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTG 1560

Qy      1575 GCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTAC 1634
Db      1561 GCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTAC 1620

Qy      1635 CAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGC 1694
Db      1621 CAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGC 1680

Qy      1695 ATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGC 1754
Db      1681 ATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGC 1740

Qy      1755 CTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCAC 1814
Db      1741 CTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCAC 1800

Qy      1815 TGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCAC 1874
Db      1801 TGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCAC 1860

Qy      1875 CTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTG 1934
Db      1861 CTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTG 1920

Qy      1935 CCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAA 1994
Db      1921 CCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAA 1980

Qy      1995 ACTACATGGGGAAAAAAAAAAAAAAAAAAA 2025
Db      1981 ACTACATGGGGAAACAGGTGCAAAAAAAAAA 2011
```

RESULT 7
ABX34032
ID ABX34032 standard; cDNA; 2498 BP.
XX
AC ABX34032;
XX
DT 10-FEB-2003 (first entry)
XX
DE Human cancer suppressing protein PP78276.
XX
KW Human; gene; ss; cancer suppressing protein; cancer.
XX
OS Homo sapiens.
XX
PN CN1351081-A.
XX
PD 29-MAY-2002.
XX
PF 31-OCT-2000; 2000CN-0127102.
XX
PR 31-OCT-2000; 2000CN-0127102.
XX
PA (SHAN-) SHANGHAI INST ONCOLOGY.
XX
PI Gu J;
XX
DR WPI; 2002-609437/66.
DR P-PSDB; ABU11286.
XX
PT New human protein with cancer cell growth suppressing function and a
PT polynucleotide encoding it, for treating diseases, such as, cancer -
XX
PS Claim 5; Page 31-33 (disclosure); 39pp; Chinese.
XX
CC This invention relates to the cDNA and protein sequences of a novel
CC human protein with cancer suppressing function. The invention also
CC comprises a method for preparing the polypeptide by recombination,
CC and an application of the polypeptide in treating diseases such as
CC cancer, etc. Also disclosed in an antagonist of the polypeptide and
CC its medical action. The present sequence represents a cDNA encoding
CC a cancer suppressing protein of the invention.
XX
SQ Sequence 2498 BP; 593 A; 798 C; 597 G; 510 T; 0 other;

Query Match 94.7%; Score 1935.2; DB 24; Length 2498;
Best Local Similarity 98.8%; Pred. No. 0;
Matches 1949; Conservative 0; Mismatches 23; Indels 0; Gaps 0;





RESULT 8
AAF25176
ID AAF25176 standard; cDNA; 1930 BP.
XX
AC AAF25176;
XX
DT 30-APR-2001 (first entry)
XX
DE Nucleotide sequence of a human protein having a hydrophobic domain.
XX
KW Human; hydrophobic protein; secretory protein; membrane protein; sepsis;
KW tumour inhibition; immune deficiency; autoimmune disorder; anaemia; burn;
KW infectious disease; cancer; ulcer; periodontal disease; coagulation;

```
KW   Parkinson's disease; fertility; immune response; thrombosis; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             82..1017
FT                   /*tag=  a
FT                   /product= "hydrophobic protein"
XX
PN   WO200104297-A2.
XX
PD   18-JAN-2001.
XX
PF   16-JUN-2000; 2000WO-JP03942.
XX
PR   08-JUL-1999;   99JP-0194359.
XX
PA   (SAGA ) SAGAMI CHEM RES CENT.
PA   (PROT-) PROTEGENE INC.
XX
PI   Kato S,  Kimura T;
XX
DR   WPI; 2001-103081/11.
DR   P-PSDB; AAB31676.
XX
PT   Isolated human proteins and polynucleotides are used in research and
PT   have activities including cell proliferation/differentiation activity,
PT   immune stimulating activity and receptor/ligand activity -
XX
PS   Claim 4; Page 144-147; 151pp; English.
XX
CC   The present sequence encodes a human protein with hydrophobic domains.
CC   AAF25166 represents a shorter version of the present sequence. The
CC   protein possesses a hydrophobic domain and so is a secretory protein
CC   or a membrane protein. The protein is used as an antigen to prepare
CC   antibodies. The polynucleotide sequence is useful as a source of probes
CC   for genetic diagnosis. It is also useful for producing the protein
CC   in large quantities and for gene therapy. The eukaryotic cells are used
CC   for detecting the receptors or ligands corresponding to the protein and
CC   for detecting small novel pharmaceuticals. The antibodies are also used
CC   for detection, quantification and purification of the proteins. Both the
CC   protein and polynucleotide may be used in research or as nutritional
CC   sources or supplements. The protein may have cytokine and cell
CC   proliferation/differentiation activity, immune stimulating or suppressing
CC   activity, hematopoiesis regulating activity, tissue growth activity,
CC   activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic
CC   and thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC   activity and tumour inhibition activity. It may therefore may be used to
CC   treat immune deficiencies resulting from autoimmune disorders or
CC   infectious diseases, cancer, sepsis, anaemias, burns and ulcers,
CC   periodontal disease, Parkinson's disease, induce fertility, improve
CC   immune response and enhance coagulation or inhibit thrombosis.
XX
SQ   Sequence 1930 BP; 356 A; 647 C; 546 G; 381 T; 0 other;

  Query Match             92.4%;  Score 1889.6;  DB 22;  Length 1930;
  Best Local Similarity   98.7%;  Pred. No. 0;
  Matches 1924;  Conservative    0;  Mismatches    4;  Indels   22;  Gaps    1;

Qy          61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||
Db           1 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGCTC 60

Qy         121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 120

Qy         181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 180

Qy         241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Db         181 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 240

Qy         301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         241 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 300

Qy         361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         301 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 360

Qy         421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         361 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 420

Qy         481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         421 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 480

Qy         541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         481 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 540

Qy         601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         541 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAACTGCAGGTGCAGACAGGCAAAGAT 600

Qy         661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCT 720
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         601 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGAGAGTGAAAACATCACGGCT 660

Qy         721 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 780
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         661 GCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTC 720

Qy         781 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 840
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         721 CTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATG 780

Qy         841 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 900
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         781 GACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGG 840

Qy         901 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 960
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         841 ATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAG 900

Qy         961 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 1020
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         901 TCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGAC 960

Qy        1021 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1080
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         961 GTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCC 1020

Qy        1081 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1140
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1021 AGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCT 1080

Qy        1141 GGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCA 1200
               |||||||||||||||||||                    ||||||||||||||||||||
Db        1081 GGCTCTGTGAGTGGCCT----------------------CTCCCTCCTGCTCTGGGCTCA 1118

Qy        1201 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1260
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1119 GATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGC 1178

Qy        1261 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1320
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1179 TGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCT 1238

Qy        1321 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1380
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        1239 GAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAG 1298
```

```
Qy       1381 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1440
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1299 CCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACA 1358

Qy       1441 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1500
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1359 AGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTC 1418

Qy       1501 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1560
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1419 CCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTC 1478

Qy       1561 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1620
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1479 TTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCC 1538

Qy       1621 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1680
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1539 CAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGG 1598

Qy       1681 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1740
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1599 CTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATAT 1658

Qy       1741 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1800
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1659 TGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGAT 1718

Qy       1801 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1860
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1719 GTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGA 1778

Qy       1861 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1920
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1779 GTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGG 1838

Qy       1921 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1980
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1839 CCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCG 1898

Qy       1981 GGATGCTATTAAAAACTACATGGGGAAAAA 2010
             |||||||||||||||||||||||||||| |
Db       1899 GGATGCTATTAAAAACTACATGGGGAAACA 1928
```

```
RESULT 9
AAF94473
ID   AAF94473 standard; cDNA; 1556 BP.
XX
AC   AAF94473;
XX
DT   04-JUN-2001  (first entry)
XX
DE   Human hydrophobic domain containing protein clone HP10727 cDNA #87.
XX
KW   Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;
KW   antianaemic; vulnerary; antiulcer; osteopathic; anti-inflammatory;
KW   cytostatic; gene therapy; autoimmune disorder; multiple sclerosis;
KW   HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;
KW   inflammatory bowel disease; nutritional supplement; appetite; vaccine;
KW   behavioural characteristic; immune response; ss.
XX
OS   Homo sapiens.
XX
PN   WO200112660-A2.
XX
PD   22-FEB-2001.
XX
PF   10-AUG-2000; 2000WO-JP05356.
XX
PR   17-AUG-1999;   99JP-0230344.
PR   07-SEP-1999;   99JP-0252551.
PR   01-OCT-1999;   99JP-0281132.
PR   22-OCT-1999;   99JP-0301624.
PR   04-NOV-1999;   99JP-0313877.
XX
PA   (SAGA ) SAGAMI CHEM RES CENT.
PA   (PROT-) PROTEGENE INC.
XX
PI   Kato S,  Kimura T;
XX
DR   WPI; 2001-160059/16.
DR   P-PSDB; AAB88583.
XX
PT   Human proteins with hydrophobic domains and the DNAs which encode them
PT   are useful for treating autoimmune disorders, burns and tumors and for
PT   screening novel pharmaceuticals -
XX
PS   Claim 4; Page 392-394; 518pp; English.
XX
CC   AAF94417 to AAF94516 encode the human proteins given in AAB88557 to
CC   AAB88606 (I) which have a hydrophobic domain. (I) have immunosuppressant,
CC   anti-HIV, neuroprotective, antianaemic, vulnerary, antiulcer,
CC   osteopathic, anti-inflammatory and cytostatic activities, and can be
CC   used in gene therapy. (I) can be used as pharmaceuticals and as antigens
CC   to prepare antibodies. DNA and cDNA (II) encoding (I) can be used as
CC   probes for genetic diagnosis and gene sources for gene therapy or for
CC   producing (I) in large quantities. Cells containing (II) are used for
CC   the detection of ligands or receptors corresponding to membrane or
CC   secretory proteins and to screen small molecule novel pharmaceuticals.
CC   Antibodies directed to (I) can be used for the detection, quantification
CC   and purification of (I). Activities of (I) may include cytokine and cell
CC   proliferation/differentiation function, immune stimulating or suppressing
CC   activity, haematopoiesis regulating activity, tissue growth activity,
CC   activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, receptor/ligand activity and anti-inflammatory
CC   activity. (I) and (II) can be used to treat autoimmune disorders e.g.
CC   multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis,
CC   inflammatory bowel disease and tumours. (I) and (II) can also be used for
CC   wound healing, as nutritional sources or supplements e.g. as amino acid,
CC   carbon or nitrogen source, to effect metabolism, catabolism, anabolism,
CC   processing and utilisation of dietary fat, protein, carbohydrate,
CC   vitamins and minerals, to effect behavioural characteristics, to affect
CC   appetite, and can act as antigens in vaccines to raise an immune response
CC   to the protein or another material cross-reactive with the protein.
XX
SQ   Sequence 1556 BP; 278 A; 521 C; 435 G; 322 T; 0 other;
```

Query Match 66.4%; Score 1356.8; DB 22; Length 1556;
Best Local Similarity 99.5%; Pred. No. 8.4e-272;
Matches 1361; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

```
Qy        651 AGGCAAAGATGCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAA 710
              ||||||||||||||||||||||||||||||||||||||||||||||||||| ||||||||
Db        183 AGGCAAAGATGCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGAGAGTGAAAA 242

Qy        711 CATCACGGCTGCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCT 770
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        243 CATCACGGCTGCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCCCCT 302

Qy        771 CATCCTGCTCCTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCT 830
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        303 CATCCTGCTCCTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGAGCT 362

Qy        831 GGTGCGGATGGACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACC 890
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        363 GGTGCGGATGGACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACCACC 422

Qy        891 TGCCCAGGGGATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCA 950
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        423 TGCCCAGGGGATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCGGCA 482

Qy        951 GCCTTCTGAGTCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGG 1010
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        483 GCCTTCTGAGTCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCCAGG 542
```

```
Qy       1011 CCCCGGAGACGTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGT 1070
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        543 CCCCGGAGACGTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGAGGT 602

Qy       1071 CATCTAGCCCAGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTG 1130
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        603 CATCTAGCCCAGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCATTTG 662

Qy       1131 AGCCAGGGCTGGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGC 1190
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        663 AGCCAGGGCTGGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGC 722

Qy       1191 TCTGGGCTCAGATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTAC 1250
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        723 TCTGGGCTCAGATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGCTAC 782

Qy       1251 ATGGGGATGCTGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCC 1310
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        783 ATGGGGATGCTGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCTCCC 842

Qy       1311 CTAGAGACCTGAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCA 1370
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        843 CTAGAGACCTGAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTCTCA 902

Qy       1371 GAACGTCCAGCCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCAT 1430
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        903 GAACGTCCAGCCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAGCAT 962

Qy       1431 CAGTGGGACAAGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGA 1490
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        963 CAGTGGGACAAGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGTGGA 1022

Qy       1491 GAGACTTCTCCCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTC 1550
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1023 GAGACTTCTCCCCCGTGGCCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTC 1082

Qy       1551 AGACTTCCTCTTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCG 1610
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1083 AGACTTCCTCTTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGCCATCG 1142

Qy       1611 CCACCTTCCCCAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGT 1670
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1143 CCACCTTCCCCAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGTTAAGT 1202

Qy       1671 CAATCTGGGGCTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGG 1730
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1203 CAATCTGGGGCTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAAACGGG 1262

Qy       1731 AAGTACATATTGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGC 1790
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1263 AAGTACATATTGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCTGAGGC 1322

Qy       1791 CAGGACAGATGTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCT 1850
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1323 CAGGACAGATGTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGCCTTCT 1382

Qy       1851 GGGAAGGTGAGTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGC 1910
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1383 GGGAAGGTGAGTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCCACTGC 1442

Qy       1911 TCAGCGCGGGCCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGA 1970
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1443 TCAGCGCGGGCCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACTTCTGA 1502

Qy       1971 GTATGAAGCGGGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAA 2018
             |||||||||||||||||||||||||||||||||||| |     |||
Db       1503 GTATGAAGCGGGATGCTATTAAAAACTACATGGGGAAACAGGTGCAAA 1550
```

RESULT 10
AAX97964
ID AAX97964 standard; DNA; 1490 BP.

XX
AC AAX97964;
XX
DT 17-SEP-1999 (first entry)
XX
DE Human secreted protein gene 49.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW foetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS; ss.
XX
OS Homo sapiens.
XX
PN WO9931117-A1.
XX
PD 24-JUN-1999.
XX
PF 17-DEC-1998; 98WO-US27059.
XX
PR 19-DEC-1997; 97US-0068369.
PR 18-DEC-1997; 97US-0068006.
PR 18-DEC-1997; 97US-0068007.
PR 18-DEC-1997; 97US-0068008.
PR 18-DEC-1997; 97US-0068053.
PR 18-DEC-1997; 97US-0068054.
PR 18-DEC-1997; 97US-0068057.
PR 18-DEC-1997; 97US-0068064.
PR 18-DEC-1997; 97US-0070923.
PR 19-DEC-1997; 97US-0068169.
PR 19-DEC-1997; 97US-0068365.
PR 19-DEC-1997; 97US-0068367.
PR 19-DEC-1997; 97US-0068368.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Carter KC, Duan RD, Feng P, Ferrie AM, Florence C;
PI Florence K, Greene JM, Janat F, Kyaw H, Moore PA;
PI Ni J, Rosen CA, Ruben SM, Shi Y, Soppet DR, Wei Y;
PI Yu G;
XX
DR WPI; 1999-418749/35.
DR P-PSDB; AAY36272.
XX
PT New isolated human genes encoding secreted polypeptides
XX
PS Claim 1; Page 301; 537pp; English.
XX
CC AAX97916 to AAX98029 represent 110 isolated human secreted protein
CC genes. AAY36224 to AAY36727 represent the secreted proteins encoded by
CC the 110 human genes. The genes and their corresponding secreted
CC polypeptides are useful for preventing, treating or ameliorating medical
CC conditions, e.g. by protein or gene therapy. Also pathological conditions
CC can be diagnosed by determining the amount of the new polypeptides in a
CC sample or by determining the presence of mutations in the new genes.
CC Specific uses are described for each of the 110 genes, based on which
CC tissues they are most highly expressed in, and include developing
CC products for the diagnosis or treatment of cancer, tumours, developmental
CC abnormalities and foetal deficiencies, blood disorders, diseases of the
CC immune system, autoimmune diseases, inflammation, allergies, Alzheimer's
CC and cognitive disorders, schizophrenia, arthritis, asthma, psoriasis,
CC sepsis, skin disorders, atherosclerosis, diabetes, cardiovascular
CC disorders, kidney disorders, digestive/endocrine disorders, infections
CC and AIDS. The polypeptides are also useful for identifying their binding
CC partners. The sequences given in AAX97907 to AAX97915 and AAY36223 are
CC used in the exemplification of the present invention.
XX
SQ Sequence 1490 BP; 318 A; 468 C; 399 G; 302 T; 3 other;

Query Match 62.8%; Score 1284.6; DB 20; Length 1490;
Best Local Similarity 98.3%; Pred. No. 7.8e-257;

```
  Matches 1316;  Conservative    3;  Mismatches   17;  Indels    3;  Gaps    2;

Qy        708 AAACATCACGGCTGCAGCCCTGGCTACGGGTGCCTGCATCGTAGGAATCCTCTGCCTCCC 767
              | |||||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||
Db        113 AGACATCACGGCTGCAGCCCTGGCTACGGGTGCCTGCATCGTA-GAATCCTCTGCCTCCC 171

Qy        768 CCTCATCCTGCTCCTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGA 827
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        172 CCTCATCCTGCTCCTGGTCTACAAGCAAAGGCAGGCAGCCTCCAACCGCCGTGCCCAGGA 231

Qy        828 GCTGGTGCGGATGGACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACC 887
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        232 GCTGGTGCGGATGGACAGCAACATTCAAGGGATTGAAAACCCCGGCTTTGAAGCCTCACC 291

Qy        888 ACCTGCCCAGGGGATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCG 947
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        292 ACCTGCCCAGGGGATACCCGAGGCCAAAGTCAGGCACCCCCTGTCCTATGTGGCCCAGCG 351

Qy        948 GCAGCCTTCTGAGTCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCC 1007
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        352 GCAGCCTTCTGAGTCTGGGCGGCATCTGCTTTCGGAGCCCAGCACCCCCCTGTCTCCTCC 411

Qy       1008 AGGCCCCGGAGACGTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGA 1067
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        412 AGGCCCCGGAGACGTCTTCTTCCCATCCCTGGACCCTGTCCCTGACTCTCCAAACTTTGA 471

Qy       1068 GGTCATCTAGCCCAGCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCAT 1127
              |||||||:|||::|||||||||||||||||||||||||||||||||||||||||||||||
Db        472 GGTCATCTAKCCCWKCTGGGGGACAGTGGGCTGTTGTGGCTGGGTCTGGGGCAGGTGCAT 531

Qy       1128 TTGAGCCAGGGCTGGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCC 1187
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        532 TTGAGCCAGGGCTGGCTCTGTGAGTGGCCTCCTTGGCCTCGGCCCTGGTTCCCTCCCTCC 591

Qy       1188 TGCTCTGGGCTCAGATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGC 1247
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        592 TGCTCTGGGCTCAGATACTGTGACATCCCAGAAGCCCAGCCCCTCAACCCCTCTGGATGC 651

Qy       1248 TACATGGGGATGCTGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCT 1307
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        652 TACATGGGGATGCTGGACGGCTCAGCCCCTGTTCCAAGGATTTTGGGGTGCTGAGATTCT 711

Qy       1308 CCCCTAGAGACCTGAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTC 1367
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        712 CCCCTAGAGACCTGAAATTCACCAGCTACAGATGCCAAATGACTTACATCTTAAGAAGTC 771

Qy       1368 TCAGAACGTCCAGCCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAG 1427
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        772 TCAGAACGTCCAGCCCTTCAGCAGCTCTCGTTCTGAGACATGAGCCTTGGGATGTGGCAG 831

Qy       1428 CATCAGTGGGACAAGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGT 1487
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        832 CATCAGTGGGACAAGATGGACACTGGGCCACCCTCCCAGGCACCAGACACAGGGCACGGT 891

Qy       1488 GGAGAGACTTCTCCCCCGTGG--CCGCCTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTT 1545
              |||||||||||||||||||  |   |||||||||||||||||||||||||||||||||||
Db        892 GGAGAGACTTCTCCCCCGTGGCACGCACTTGGCTCCCCCGTTTTGCCCGAGGCTGCTCTT 951

Qy       1546 CTGTCAGACTTCCTCTTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGC 1605
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        952 CTGTCAGACTTCCTCTTTGTACCACAGTGGCTCTGGGGCCAGGCCTGCCTGCCCACTGGC 1011

Qy       1606 CATCGCCACCTTCCCCAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGT 1665
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1012 CATCGCCACCTTCCCCAGCTGCCTCCTACCAGCAGTTTCTCTGAAGATCTGTCAACAGGT 1071

Qy       1666 TAAGTCAATCTGGGGCTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAA 1725
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1072 TAAGTCAATCTGGGGCTTCCACTGCCTGCATTCCAGTCCCCAGAGCTTGGTGGTCCCGAA 1131

Qy       1726 ACGGGAAGTACATATTGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCT 1785
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1132 ACGGGAAGTACATATTGGGGCATGGTGGCCTCCGTGAGCAAATGGTGTCTTGGGCAATCT 1191

Qy       1786 GAGGCCAGGACAGATGTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGC 1845
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1192 GAGGCCAGGACAGATGTTGCCCCACCCACTGGAGATGGTGCTGAGGGAGGTGGGTGGGGC 1251

Qy       1846 CTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCC 1905
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1252 CTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGCCCCCCGCCCTCCCCATCCCCTACTCCC 1311

Qy       1906 ACTGCTCAGCGCGGGCCATTGCAAGGGTGCCACACAATGTCTTGTCCACCCTGGGACACT 1965
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1312 ACTGCTCAGCGCGGGCCATTGCAAGGGTGCCACACAATGTTTTGTCCACCCTGGGACACT 1371

Qy       1966 TCTGAGTATGAAGCGGGATGCTATTAAAAACTACATGGGGAAAAAAAAAAAAAAAAAAAA 2025
              |||||||||||||||||||||||||||||||||||||||||||| |    |||    ||
Db       1372 TCTGAGTATGAAGCGGGATGCTATTAAAAACTACATGGGGAAACAGGTGCAAACCCTGAA 1431

Qy       2026 AAAAAAAAAAAAAAAAAGA 2044
              |||||||||||||||||| |
Db       1432 AAAAAAAAAAAAAAAAAAA 1450
```

RESULT 11
AAS97018
ID AAS97018 standard; cDNA; 1188 BP.
XX
AC AAS97018;
XX
DT 26-FEB-2002 (first entry)
XX
DE DNA encoding human anticancer protein #8.
XX
KW Human; anticancer; cancer; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN CN1313298-A.
XX
PD 19-SEP-2001.
XX
PF 09-MAR-2000; 2000CN-0111949.
XX
PR 09-MAR-2000; 2000CN-0111949.
XX
PA (SHAN-) SHANGHAI INST ONCOLOGY.
XX
PI Gu J, Yang S;
XX
DR WPI; 2002-042186/06.
DR P-PSDB; AAU72795.
XX
PT Human protein able to suppress growth of cancer cells and its coding
PT sequence -
XX
PS Disclosure; Page 29; 38pp; Chinese.
XX
CC The invention relates to a human protein with cancer suppressing
CC function, and the polynucleotide encoding it. Also described is the
CC process for preparing the polypeptide by recombination, the application
CC of the polypeptide in treating diseases such as cancer, the antagonist of
CC the polypeptide and its medical function, and the application of the
CC polynucleotide. AAS97011-AAS97043 represent human anticancer coding
CC sequences and PCR primers of the invention.
XX
SQ Sequence 1188 BP; 241 A; 374 C; 322 G; 251 T; 0 other;

```
  Query Match             56.5%;  Score 1155.8;  DB 24;  Length 1188;
  Best Local Similarity   98.6%;  Pred. No. 3.7e-230;
  Matches 1166;  Conservative    0;  Mismatches   17;  Indels    0;  Gaps    0;

Qy        862 GAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGGATACCCGAGGCCAAAGTCAGG 921
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 GAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGGATACCCGAGGCCAAAGTCAGG 60
```

```
Qy       922 CACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAGTCTGGGCGGCATCTGCTTTCG 981
Db        61 CACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAGTCTGGGCGGCATCTGCTTTCG 120

Qy       982 GAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATCCCTGGAC 1041
Db       121 GAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATCCCTGGAC 180

Qy      1042 CCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGTGGGCTGT 1101
Db       181 CCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGTGGGCTGT 240

Qy      1102 TGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGGCCTCCTT 1161
Db       241 TGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGGCCTCCTT 300

Qy      1162 GGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATCCCAGAAG 1221
Db       301 GGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATCCCAGAAG 360

Qy      1222 CCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCCCCTGTTC 1281
Db       361 CCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCCCCTGTTC 420

Qy      1282 CAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCTACAGATG 1341
Db       421 CAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCTACAGATG 480

Qy      1342 CCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTCTCGTTCT 1401
Db       481 CCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTCTCGTTCT 540

Qy      1402 GAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGGCCACCCT 1461
Db       541 GAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGGCCACCCT 600

Qy      1462 CCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCTTGGCTCC 1521
Db       601 CCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCTTGGCTCC 660

Qy      1522 CCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTGGCTCTGG 1581
Db       661 CCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTGGCTCTGG 720

Qy      1582 GGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTACCAGCAGT 1641
Db       721 GGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTACCAGCAGT 780

Qy      1642 TTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGCATTCCAG 1701
Db       781 TTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGCATTCCAG 840

Qy      1702 TCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGCCTCCGTG 1761
Db       841 TCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGCCTCCGTG 900

Qy      1762 AGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCACTGGAGAT 1821
Db       901 AGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCACTGGAGAT 960

Qy      1822 GGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGCCCC 1881
Db       961 GGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAAGAAGGCACCTGCCCC 1020

Qy      1882 CCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTGCCACACA 1941
Db      1021 CCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTGCCACACA 1080

Qy      1942 ATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAAACTACAT 2001
Db      1081 ATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAAACTACAT 1140

Qy      2002 GGGGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGA 2044
Db      1141 GGGGAAACAGGTGCAAACCCTGGAAAAAAAAAAAAAAAAAAAAA 1183
```

RESULT 12
AAS62589
ID AAS62589 standard; cDNA; 1016 BP.
XX
AC AAS62589;
XX
DT 14-FEB-2002 (first entry)
XX
DE cDNA sequence #376 encoding novel human secreted protein.
XX
KW Human secreted protein; hyperproliferative disorder; autoimmune disorder;
KW immune deficiency disorder; blood disorder; inflammatory disorder;
KW infectious disorder; gene therapy; antimicrobial; hepatotropic;
KW immunosuppressive; antirheumatic; ss.
XX
OS Homo sapiens.
XX
PN WO200177291-A2.
XX
PD 18-OCT-2001.
XX
PF 29-MAR-2001; 2001WO-US10485.
XX
PR 06-APR-2000; 2000US-195604P.
XX
PA (GEMY) GENETICS INST INC.
XX
PI Wong GG, Clark HF, Fechtel K, Agostino MJ, Howes SH, Resnick RJ;
PI Gulukota K, Graham JR;
XX
DR WPI; 2002-010900/01.
XX
PT New polynucleotides encoding secreted proteins useful for treating e.g.
PT asthma, HIV and Crohn's disease -
XX
PS Claim 1; Page 273; 391pp; English.
XX
CC The present invention relates to the isolation of novel cDNA sequences
CC which encode human secreted proteins. The cDNA sequences have been
CC derived from a variety of human tissues. The invention also provides
CC a method for producing proteins from these polynucleotide sequences.
CC The proteins are useful for identifying compounds that modulate their
CC activity and production, and the cell is also useful for identifying
CC compounds that modulate expression of the polynucleotide sequences
CC encoding the secreted proteins. The sequences of the invention are
CC useful for treating diseases such as hyperproliferative disorders
CC (e.g. cancer), immune deficiency disorders (e.g. severe combined
CC immunodeficiency (SCID)), autoimmune disorders (e.g. multiple
CC sclerosis), blood disorders (e.g. thrombocytopaenia), inflammatory
CC disorders (e.g. arthritis) and infectious disorders (e.g. hepatitis).
CC The polynucleotide sequences of the invention are also useful in gene
CC therapy. AAS62214-AAS62838 represent the cDNA sequences of the
CC invention that encode for novel human secreted proteins.
XX
SQ Sequence 1016 BP; 183 A; 323 C; 283 G; 227 T; 0 other;

Query Match 49.7%; Score 1016; DB 24; Length 1016;
Best Local Similarity 100.0%; Pred. No. 3.5e-201;
Matches 1016; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       990 CACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATCCCTGGACCCTGTCCC 1049
Db         1 CACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATCCCTGGACCCTGTCCC 60

Qy      1050 TGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGTGGGCTGTTGTGGCTG 1109
Db        61 TGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGTGGGCTGTTGTGGCTG 120
```

```
Qy       1110 GGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGGCCTCCTTGGCCTCGG 1169
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 GGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGGCCTCCTTGGCCTCGG 180

Qy       1170 CCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATCCCAGAAGCCCAGCCC 1229
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 CCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATCCCAGAAGCCCAGCCC 240

Qy       1230 CTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCCCCTGTTCCAAGGATT 1289
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 CTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCCCCTGTTCCAAGGATT 300

Qy       1290 TTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCTACAGATGCCAAATGA 1349
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 TTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCTACAGATGCCAAATGA 360

Qy       1350 CTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTCTCGTTCTGAGACATG 1409
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 CTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTCTCGTTCTGAGACATG 420

Qy       1410 AGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGGCCACCCTCCCAGGCA 1469
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 AGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGGCCACCCTCCCAGGCA 480

Qy       1470 CCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCTTGGCTCCCCCGTTTT 1529
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 CCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCTTGGCTCCCCCGTTTT 540

Qy       1530 GCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTGGCTCTGGGGCCAGGC 1589
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        541 GCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTGGCTCTGGGGCCAGGC 600

Qy       1590 CTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTACCAGCAGTTTCTCTGA 1649
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 CTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTACCAGCAGTTTCTCTGA 660

Qy       1650 AGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGCATTCCAGTCCCCAGA 1709
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 AGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGCATTCCAGTCCCCAGA 720

Qy       1710 GCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGCCTCCGTGAGCAAATG 1769
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 GCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGCCTCCGTGAGCAAATG 780

Qy       1770 GTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCACTGGAGATGGTGCTGA 1829
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 GTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCACTGGAGATGGTGCTGA 840

Qy       1830 GGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGCCCCCCGCCCTC 1889
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 GGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGCCCCCCGCCCTC 900

Qy       1890 CCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTGCCACACAATGTCTTG 1949
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        901 CCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTGCCACACAATGTCTTG 960

Qy       1950 TCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAAACTACATGGGG 2005
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        961 TCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAAACTACATGGGG 1016
```

RESULT 13
AAK85139
ID AAK85139 standard; DNA; 5920 BP.
XX
AC AAK85139;
XX
DT 07-NOV-2001 (first entry)
XX
DE Human immune/haematopoietic antigen genomic sequence SEQ ID NO:39951.
XX
KW Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS Homo sapiens.
XX
PN WO200157182-A2.
XX
PD 09-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01354.
XX
PR 31-JAN-2000; 2000US-0179065.
PR 04-FEB-2000; 2000US-0180628.
PR 24-FEB-2000; 2000US-0184664.
PR 02-MAR-2000; 2000US-0186350.
PR 16-MAR-2000; 2000US-0189874.
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123.
PR 19-MAY-2000; 2000US-0205515.
PR 07-JUN-2000; 2000US-0209467.
PR 28-JUN-2000; 2000US-0214886.
PR 30-JUN-2000; 2000US-0215135.
PR 07-JUL-2000; 2000US-0216647.
PR 07-JUL-2000; 2000US-0216880.
PR 11-JUL-2000; 2000US-0217487.
PR 11-JUL-2000; 2000US-0217496.
PR 14-JUL-2000; 2000US-0218290.
PR 26-JUL-2000; 2000US-0220963.
PR 26-JUL-2000; 2000US-0220964.
PR 14-AUG-2000; 2000US-0224518.
PR 14-AUG-2000; 2000US-0224519.
PR 14-AUG-2000; 2000US-0225213.
PR 14-AUG-2000; 2000US-0225214.
PR 14-AUG-2000; 2000US-0225266.
PR 14-AUG-2000; 2000US-0225267.
PR 14-AUG-2000; 2000US-0225268.
PR 14-AUG-2000; 2000US-0225270.
PR 14-AUG-2000; 2000US-0225447.
PR 14-AUG-2000; 2000US-0225757.
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759.
PR 18-AUG-2000; 2000US-0226279.
PR 22-AUG-2000; 2000US-0226681.
PR 22-AUG-2000; 2000US-0226868.
PR 22-AUG-2000; 2000US-0227182.
PR 23-AUG-2000; 2000US-0227009.
PR 30-AUG-2000; 2000US-0228924.
PR 01-SEP-2000; 2000US-0229287.
PR 01-SEP-2000; 2000US-0229343.
PR 01-SEP-2000; 2000US-0229344.
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509.
PR 05-SEP-2000; 2000US-0229513.
PR 06-SEP-2000; 2000US-0230437.
PR 06-SEP-2000; 2000US-0230438.
PR 08-SEP-2000; 2000US-0231242.
PR 08-SEP-2000; 2000US-0231243.
PR 08-SEP-2000; 2000US-0231244.
PR 08-SEP-2000; 2000US-0231413.
PR 08-SEP-2000; 2000US-0231414.
PR 08-SEP-2000; 2000US-0232080.
PR 08-SEP-2000; 2000US-0232081.
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397.
PR 14-SEP-2000; 2000US-0232398.
PR 14-SEP-2000; 2000US-0232399.
PR 14-SEP-2000; 2000US-0232400.
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063.
PR 14-SEP-2000; 2000US-0233064.
PR 14-SEP-2000; 2000US-0233065.
PR 21-SEP-2000; 2000US-0234223.
PR 21-SEP-2000; 2000US-0234274.
PR 25-SEP-2000; 2000US-0234997.
PR 25-SEP-2000; 2000US-0234998.

PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526.
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251988.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX

PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-483426/52.
XX
PT Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT useful for preventing, diagnosing and/or treating cancers and
PT metastasis -
XX
PS Disclosure; SEQ ID NO 39951; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC activity, and can be used in gene therapy and vaccine production. (I)
CC proteins and polynucleotides may be used in the prevention, diagnosis and
CC treatment of diseases associated with inappropriate (I) expression. For
CC example, they may be used to treat disorders associated with decreased
CC expression by rectifying mutations or deletions in a patient's genome
CC that affect the activity of (I) by expressing inactive proteins or to
CC supplement the patients own production of (I). Additionally, (I)
CC polynucleotides may be used to produce the secreted (I), by inserting
CC the nucleic acids into a host cell and culturing the cell to express the
CC protein. (I) proteins and polynucleotides may be used to prevent,
CC diagnose and treat immune/haematopoietic-related diseases, especially
CC cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC to AAK87694 represent human immune/haematopoietic antigen genomic
CC sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 5920 BP; 1253 A; 1607 C; 1748 G; 1312 T; 0 other;

Query Match 47.5%; Score 970.4; DB 22; Length 5920;
Best Local Similarity 99.4%; Pred. No. 1.5e-191;
Matches 974; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 1039 GACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGTGGGC 1098
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4178 GACCCTGTCCCTGACTCTCCAAACTTTGAGGTCATCTAGCCCAGCTGGGGGACAGTGGGC 4237

Qy 1099 TGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGGCCTC 1158
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4238 TGTTGTGGCTGGGTCTGGGGCAGGTGCATTTGAGCCAGGGCTGGCTCTGTGAGTGGCCTC 4297

Qy 1159 CTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATCCCAG 1218
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4298 CTTGGCCTCGGCCCTGGTTCCCTCCCTCCTGCTCTGGGCTCAGATACTGTGACATCCCAG 4357

Qy 1219 AAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCCCCTG 1278
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4358 AAGCCCAGCCCCTCAACCCCTCTGGATGCTACATGGGGATGCTGGACGGCTCAGCCCCTG 4417

Qy 1279 TTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCTACAG 1338
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4418 TTCCAAGGATTTTGGGGTGCTGAGATTCTCCCCTAGAGACCTGAAATTCACCAGCTACAG 4477

Qy 1339 ATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTCTCGT 1398
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4478 ATGCCAAATGACTTACATCTTAAGAAGTCTCAGAACGTCCAGCCCTTCAGCAGCTCTCGT 4537

Qy 1399 TCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGGCCAC 1458
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4538 TCTGAGACATGAGCCTTGGGATGTGGCAGCATCAGTGGGACAAGATGGACACTGGGCCAC 4597

Qy 1459 CCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCTTGGC 1518
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4598 CCTCCCAGGCACCAGACACAGGGCACGGTGGAGAGACTTCTCCCCCGTGGCCGCCTTGGC 4657

Qy 1519 TCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTGGCTC 1578
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 4658 TCCCCCGTTTTGCCCGAGGCTGCTCTTCTGTCAGACTTCCTCTTTGTACCACAGTGGCTC 4717

Qy 1579 TGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTACCAGC 1638

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4718 TGGGGCCAGGCCTGCCTGCCCACTGGCCATCGCCACCTTCCCCAGCTGCCTCCTACCAGC 4777

Qy       1639 AGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGCATTC 1698
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4778 AGTTTCTCTGAAGATCTGTCAACAGGTTAAGTCAATCTGGGGCTTCCACTGCCTGCATTC 4837

Qy       1699 CAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGCCTCC 1758
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4838 CAGTCCCCAGAGCTTGGTGGTCCCGAAACGGGAAGTACATATTGGGGCATGGTGGCCTCC 4897

Qy       1759 GTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCACTGGA 1818
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4898 GTGAGCAAATGGTGTCTTGGGCAATCTGAGGCCAGGACAGATGTTGCCCCACCCACTGGA 4957

Qy       1819 GATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGC 1878
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       4958 GATGGTGCTGAGGGAGGTGGGTGGGGCCTTCTGGGAAGGTGAGTGGAGAGGGGCACCTGC 5017

Qy       1879 CCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTGCCAC 1938
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       5018 CCCCCGCCCTCCCCATCCCCTACTCCCACTGCTCAGCGCGGGCCATTGCAAGGGTGCCAC 5077

Qy       1939 ACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAAACTA 1998
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       5078 ACAATGTCTTGTCCACCCTGGGACACTTCTGAGTATGAAGCGGGATGCTATTAAAAACTA 5137

Qy       1999 CATGGGGAAAAAAAAAAAAA 2018
                |||||||||| |    |||
Db       5138 CATGGGGAAACAGGTGCAAA 5157
```

RESULT 14
AAF25166
ID AAF25166 standard; cDNA; 933 BP.
XX
AC AAF25166;
XX
DT 30-APR-2001 (first entry)
XX
DE Nucleotide sequence of a human protein having a hydrophobic domain.
XX
KW Human; hydrophobic protein; secretory protein; membrane protein; sepsis;
KW tumour inhibition; immune deficiency; autoimmune disorder; anaemia; burn;
KW infectious disease; cancer; ulcer; periodontal disease; coagulation;
KW Parkinson's disease; fertility; immune response; thrombosis; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..933
FT /*tag= a
FT /product= "hydrophobic protein"
FT /note= "no termination codon given"
XX
PN WO200104297-A2.
XX
PD 18-JAN-2001.
XX
PF 16-JUN-2000; 2000WO-JP03942.
XX
PR 08-JUL-1999; 99JP-0194359.
XX
PA (SAGA) SAGAMI CHEM RES CENT.
PA (PROT-) PROTEGENE INC.
XX
PI Kato S, Kimura T;
XX
DR WPI; 2001-103081/11.
DR P-PSDB; AAB31676.
XX
PT Isolated human proteins and polynucleotides are used in research and
PT have activities including cell proliferation/differentiation activity,
PT immune stimulating activity and receptor/ligand activity -
XX
PS Claim 3; Page 114-115; 151pp; English.
XX
CC The present sequence encodes a human protein with hydrophobic domains.
CC AAF25176 represents a longer version of the present sequence. The
CC protein possesses a hydrophobic domain and so is a secretory protein
CC or a membrane protein. The protein is used as an antigen to prepare
CC antibodies. The polynucleotide sequence is useful as a source of probes
CC for genetic diagnosis. It is also useful for producing the protein
CC in large quantities and for gene therapy. The eukaryotic cells are used
CC for detecting the receptors or ligands corresponding to the protein and
CC for detecting small novel pharmaceuticals. The antibodies are also used
CC for detection, quantification and purification of the proteins. Both the
CC protein and polynucleotide may be used in research or as nutritional
CC sources or supplements. The protein may have cytokine and cell
CC proliferation/differentiation activity, immune stimulating or suppressing
CC activity, hematopoiesis regulating activity, tissue growth activity,
CC activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic
CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC activity and tumour inhibition activity. It may therefore may be used to
CC treat immune deficiencies resulting from autoimmune disorders or
CC infectious diseases, cancer, sepsis, anaemias, burns and ulcers,
CC periodontal disease, Parkinson's disease, induce fertility, improve
CC immune response and enhance coagulation or inhibit thrombosis.
XX
SQ Sequence 933 BP; 173 A; 333 C; 255 G; 172 T; 0 other;

Query Match 45.5%; Score 929.8; DB 22; Length 933;
Best Local Similarity 99.8%; Pred. No. 2.6e-183;
Matches 931; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy        142 ATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGCTGGGGATCCCTGCTCTTCGCT 201
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 ATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGCTGGGGATCCCTGCTCTTCGCT 60

Qy        202 CTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTCAAGGTCGCCACGCCGTATTCC 261
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 CTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTCAAGGTCGCCACGCCGTATTCC 120

Qy        262 CTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACCTGCAGGCTCTTGGGCCCTGTG 321
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 CTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACCTGCAGGCTCTTGGGCCCTGTG 180

Qy        322 GACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTACCGCAGCTCGAGGGGCGAGGTG 381
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 GACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTACCGCAGCTCGAGGGGCGAGGTG 240

Qy        382 CAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACGTTCCAGGACCTTCACCTGCAC 441
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 CAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACGTTCCAGGACCTTCACCTGCAC 300

Qy        442 CATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTGGCTCAGCGCCACGGGCTGGAG 501
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        301 CATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTGGCTCAGCGCCACGGGCTGGAG 360

Qy        502 TCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATGCGCAACCTGACCCTGCTGGAT 561
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        361 TCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATGCGCAACCTGACCCTGCTGGAT 420

Qy        562 AGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCACCACCACTCGGAGCACAGGGTC 621
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        421 AGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCACCACCACTCGGAGCACAGGGTC 480

Qy        622 CATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGATGCACCATCCAACTGTGTGGTG 681
                |||||||||||||| ||||||||||||||||||||||||||||||||||||||||||||||||
Db        481 CATGGTGCCATGGAACTGCAGGTGCAGACAGGCAAAGATGCACCATCCAACTGTGTGGTG 540

Qy        682 TACCCATCCTCCTCCCAGGATAGTGAAAACATCACGGCTGCAGCCCTGGCTACGGGTGCC 741
                |||||||||||||||||||| ||||||||||||||||||||||||||||||||||||||||
Db        541 TACCCATCCTCCTCCCAGGAGAGTGAAAACATCACGGCTGCAGCCCTGGCTACGGGTGCC 600

Qy        742 TGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTCCTGGTCTACAAGCAAAGGCAG 801
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        601 TGCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTGCTCCTGGTCTACAAGCAAAGGCAG 660

Qy        802 GCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATGGACAGCAACATTCAAGGGATT 861
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        661 GCAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGCGGATGGACAGCAACATTCAAGGGATT 720

Qy        862 GAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGGATACCCGAGGCCAAAGTCAGG 921
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        721 GAAAACCCCGGCTTTGAAGCCTCACCACCTGCCCAGGGGATACCCGAGGCCAAAGTCAGG 780

Qy        922 CACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAGTCTGGGCGGCATCTGCTTTCG 981
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        781 CACCCCCTGTCCTATGTGGCCCAGCGGCAGCCTTCTGAGTCTGGGCGGCATCTGCTTTCG 840

Qy        982 GAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATCCCTGGAC 1041
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        841 GAGCCCAGCACCCCCCTGTCTCCTCCAGGCCCCGGAGACGTCTTCTTCCCATCCCTGGAC 900

Qy       1042 CCTGTCCCTGACTCTCCAAACTTTGAGGTCATC 1074
                ||||||||||||||||||||||||||||||||
Db        901 CCTGTCCCTGACTCTCCAAACTTTGAGGTCATC 933
```

RESULT 15
ABA00061/c
ID ABA00061 standard; cDNA; 6197 BP.
XX
AC ABA00061;
XX
DT 25-OCT-2002 (first entry)
XX
DE CADHP-8 coding sequence, Incyte ID No: 4099073CB1.
XX
KW Gene; human; cell adhesion protein; CADHP; AIDS; Alzheimer's disease;
KW acquired immunodeficiency syndrome; thymic dysplasia; epilepsy;
KW renal tubular acidosis; congenital glaucoma; cancer; atherosclerosis;
KW Parkinson's disease; ss.
XX
OS Homo sapiens.
XX
FH Key   Location/Qualifiers
FT CDS   1149..6008
FT   /*tag= a
FT   /product= "CADHP-8"
XX
PN WO200259312-A2.
XX
PD 01-AUG-2002.
XX
PF 18-DEC-2001; 2001WO-US49206.
XX
PR 18-DEC-2000; 2000US-256542P.
PR 22-DEC-2000; 2000US-259604P.
PR 05-JAN-2001; 2001US-260101P.
XX
PA (INCY-) INCYTE GENOMICS INC.
XX
PI Duggan BM, Xu Y, Lee EA, Lee S, Lu DAM, Warren BA, Yue H;
PI Gietzen KJ, Honchell CD, Burford N, Baughn MR, Tang TY;
PI Hillman JL, Gandhi AR, Kallick DA, Bandman O, Graul RC, Walia NK;
PI Lu Y, Ramkumar J, Yao MG, Lal PG;
XX
DR WPI; 2002-590826/63.
DR P-PSDB; AAG79419.
XX
PT New human cell adhesion proteins (CADHP) useful for treating,
PT diagnosing and preventing diseases or conditions associated with the
PT aberrant CADHP expression e.g. cancer, acquired immunodeficiency
PT syndrome, Alzheimer's disease and epilepsy -
XX
PS Claim 5; Page 144-45; 149pp; English.
XX
CC The sequences given in ABA00054-63 encode novel human cell adhesion
CC proteins (CADHP). The CADHP polypeptides and polynucleotides are useful
CC in treating, diagnosing and preventing diseases or conditions associated
CC with the decreased expression or overexpression of CADHP, e.g. immune
CC system (acquired immunodeficiency syndrome, thymic dysplasia),
CC neurological (Alzheimer's disease, Parkinson's disease, epilepsy),
CC developmental (renal tubular acidosis, congenital glaucoma) and cell
CC proliferative (cancer, atherosclerosis) disorders. They are also useful
CC in assessing the effects of exogenous compounds on the expression of
CC nucleic acid and amino acid sequences of CADHP. The CADHP or its
CC fragments are useful in screening compounds for effectiveness as
CC agonist or antagonist of the polypeptides, or in altering the
CC expression of the target polynucleotide and compounds that specifically
CC bind to or modulate the activity of the polypeptide. The protein
CC encoded by this cDNA sequence shows homology to human cadherin-23.
XX
SQ Sequence 6197 BP; 1314 A; 1931 C; 1802 G; 1150 T; 0 other;

Query Match 37.7%; Score 770.4; DB 24; Length 6197;
Best Local Similarity 97.5%; Pred. No. 4.5e-150;
Matches 825; Conservative 0; Mismatches 16; Indels 5; Gaps 4;

```
Qy          1 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db       1010 GGGGGCGGGTGCCTGGAGCACGGCGCTGGGGCCGCCCGCAGCGCTCACTCGCTCGCACTC 951

Qy         61 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        950 AGTCGCGGGAGGCTTCCCCGCGCCGGCCGCGTCCCGCCCGCTCCCCGGCACCAGAAGTTC 891

Qy        121 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        890 CTCTGCGCGTCCGACGGCGACATGGGCGTCCCCACGGCCCTGGAGGCCGGCAGCTGGCGC 831

Qy        181 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        830 TGGGGATCCCTGCTCTTCGCTCTCTTCCTGGCTGCGTCCCTAGGTCCGGTGGCAGCCTTC 771

Qy        241 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        770 AAGGTCGCCACGCCGTATTCCCTGTATGTCTGTCCCGAGGGGCAGAACGTCACCCTCACC 711

Qy        301 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 360
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        710 TGCAGGCTCTTGGGCCCTGTGGACAAAGGGCACGATGTGACCTTCTACAAGACGTGGTAC 651

Qy        361 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 420
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        650 CGCAGCTCGAGGGGCGAGGTGCAGACCTGCTCAGAGCGCCGGCCCATCCGCAACCTCACG 591

Qy        421 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 480
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        590 TTCCAGGACCTTCACCTGCACCATGGAGGCCACCAGGCTGCCAACACCAGCCACGACCTG 531

Qy        481 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 540
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        530 GCTCAGCGCCACGGGCTGGAGTCGGCCTCCGACCACCATGGCAACTTCTCCATCACCATG 471

Qy        541 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 600
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        470 CGCAACCTGACCCTGCTGGATAGCGGCCTCTACTGCTGCCTGGTGGTGGAGATCAGGCAC 411

Qy        601 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 660
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        410 CACCACTCGGAGCACAGGGTCCATGGTGCCATGGAGCTGCAGGTGCAGACAGGCAAAGAT 351

Qy        661 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGATAGTGAAAACATCAC-GGC 719
              |||||||||||||||||||||||||||||||||||||||| |||||||||||||| |||
Db        350 GCACCATCCAACTGTGTGGTGTACCCATCCTCCTCCCAGGAGAGTGAAAACATCACGGGC 291

Qy        720 TGCAGCCCTGGCTACGGGTGCCT-GCATCGTAGGAATCCTCTGCCTCCCCCTCATCCTG- 777
              |||||||||||||||||||||| | |||||||||||||||||||| ||||||||
Db        290 TGCAGCCCTGGCTACGGGTGCCTGGAATCGTAGGAATCCTCTGCCTCCCCTTCATCCTGT 231
```

```
Qy        778 CTCCTGGTCTACAAGCAAAGGCAGG--CAGCCTCCAACCGCCGTGCCCAGGAGCTGGTGC 835
              ||||||||||||||||||||||||     ||  | | | || ||||||||||||  | |
Db        230 CTCCTGGTCTACAAGCAAAGGCAGGGCAGGCTCCAACCGGCGGTGCCCAGGAGCCTGGGG 171

Qy        836 GGATGG 841
              || |||
Db        170 GGCTGG 165
```

Search completed: January 8, 2004, 17:50:28
Job time : 540 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: January 8, 2004, 17:50:35 ; Search time 71 Seconds
(without alignments)
695.267 Million cell updates/sec

Title: US-10-006-485A-140
Perfect score: 1651
Sequence: 1 MGVPTALEAGSWRWGSLLFA.....GDVFFPSLDPVPDSPNPEVI 311

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	1651	100.0	311	21	AAY99381	Human PRO1412 (UNQ
2	1651	100.0	311	22	AAB66130	Protein of the inv
3	1651	100.0	311	23	ABB95521	Human angiogenesis
4	1651	100.0	311	23	ABB84915	Human PRO1412 prot
5	1651	100.0	311	23	AAU83678	Human PRO protein,
6	1647	99.8	311	22	AAB31676	Amino acid sequenc
7	1640	99.3	311	21	AAY87247	Human signal pepti
8	1030	62.4	193	23	ABG70193	Human prey protein
9	931	56.4	179	23	ABU11286	cDNA encoding huma
10	889	53.8	1509	22	ABG03875	Novel human diagno
11	783.5	47.5	168	22	AAB88583	Human hydrophobic
12	589	35.7	110	21	AAB40620	Human ORFX ORF384
13	556	33.7	177	20	AAY36634	Fragment of human
14	136	8.2	174	20	AAY36272	Human secreted pro
15	130	7.9	25	20	AAY36636	Fragment of human
16	125	7.6	480	23	AAU81008	BSL1-Ig fusion con
17	114.5	6.9	612	23	ABB82158	Human NOV4 protein
18	112.5	6.8	215	20	AAY41707	Human PRO386 prote
19	112.5	6.8	215	21	AAB44263	Human PRO386 (UNQ3
20	112.5	6.8	215	21	AAY70465	Human membrane cha
21	112.5	6.8	215	22	AAU29057	Human PRO polypept
22	112.5	6.8	215	23	ABB08950	Human SCN2B. Homo
23	112.5	6.8	215	24	ABU71145	Human PRO386 prote
24	112.5	6.8	215	24	ABU65602	Human secreted/tra
25	112.5	6.8	215	24	ABU65935	Novel human secret
26	112.5	6.8	215	24	ABU67439	Human secreted/tra
27	112.5	6.8	215	24	ABU61093	Human PRO386 polyp
28	112.5	6.8	215	24	ABU65297	Human PRO polypept
29	112.5	6.8	215	24	ABU58433	Human PRO polypept
30	112.5	6.8	215	24	ABU55969	Human secreted/tra
31	112.5	6.8	215	24	ABU56964	Human PRO polypept
32	112.5	6.8	215	24	ABU10543	Human secreted/tra
33	112.5	6.8	290	22	AAU03560	Mouse immunoregula
34	112.5	6.8	290	22	AAY72678	Murine B7-4 protei
35	112.5	6.8	290	22	AAY72646	Murine B7-4 protei
36	112.5	6.8	290	23	AAO15819	Murine B7H1 protei
37	112.5	6.8	290	23	AAE16963	Mouse PD-1 ligand
38	112.5	6.8	290	24	ABG75660	Murine PD-L1 polyp
39	112.5	6.8	290	24	AAE33392	Murine B7-4 protei
40	112.5	6.8	290	24	ABJ18520	Murine PD-L1 prote
41	110.5	6.7	1694	22	AAE09449	Human sbg24878SIa
42	110.5	6.7	1709	22	AAE09448	Human sbg24878SIa
43	110.5	6.7	1839	22	ABG10466	Novel human diagno
44	108.5	6.6	279	22	AAU01370	Mouse TANGO 509 am
45	108.5	6.6	279	22	AAU01413	Mouse TANGO 509, v

ALIGNMENTS

RESULT 1
AAY99381
ID AAY99381 standard; Protein; 311 AA.
XX
AC AAY99381;
XX
DT 08-AUG-2000 (first entry)
XX
DE Human PRO1412 (UNQ730) amino acid sequence SEQ ID NO:140.
XX
KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening.
XX
OS Homo sapiens.
XX
PN WO200012708-A2.
XX
PD 09-MAR-2000.
XX
PF 01-SEP-1999; 99WO-US20111.
XX
PR 01-SEP-1998; 98US-0098716.
PR 01-SEP-1998; 98US-0098749.
PR 01-SEP-1998; 98US-0098750.
PR 02-SEP-1998; 98US-0098803.
PR 02-SEP-1998; 98US-0098821.
PR 02-SEP-1998; 98US-0098843.
PR 09-SEP-1998; 98US-0099536.
PR 09-SEP-1998; 98US-0099596.
PR 09-SEP-1998; 98US-0099598.
PR 09-SEP-1998; 98US-0099602.
PR 09-SEP-1998; 98US-0099642.

PR 10-SEP-1998; 98US-0099741.
PR 10-SEP-1998; 98US-0099754.
PR 10-SEP-1998; 98US-0099763.
PR 10-SEP-1998; 98US-0099792.
PR 10-SEP-1998; 98US-0099808.
PR 10-SEP-1998; 98US-0099812.
PR 10-SEP-1998; 98US-0099815.
PR 10-SEP-1998; 98US-0099816.
PR 15-SEP-1998; 98US-0100385.
PR 15-SEP-1998; 98US-0100388.
PR 15-SEP-1998; 98US-0100390.
PR 16-SEP-1998; 98US-0100584.
PR 16-SEP-1998; 98US-0100627.
PR 16-SEP-1998; 98US-0100661.
PR 16-SEP-1998; 98US-0100662.
PR 16-SEP-1998; 98US-0100664.
PR 17-SEP-1998; 98US-0100683.
PR 17-SEP-1998; 98US-0100684.
PR 17-SEP-1998; 98US-0100710.
PR 17-SEP-1998; 98US-0100711.
PR 17-SEP-1998; 98US-0100919.
PR 17-SEP-1998; 98US-0100930.
PR 18-SEP-1998; 98US-0100848.
PR 18-SEP-1998; 98US-0100849.
PR 18-SEP-1998; 98US-0101014.
PR 18-SEP-1998; 98US-0101068.
PR 18-SEP-1998; 98US-0101071.
PR 22-SEP-1998; 98US-0101279.
PR 23-SEP-1998; 98US-0101471.
PR 23-SEP-1998; 98US-0101472.
PR 23-SEP-1998; 98US-0101474.
PR 23-SEP-1998; 98US-0101475.
PR 23-SEP-1998; 98US-0101476.
PR 23-SEP-1998; 98US-0101477.
PR 23-SEP-1998; 98US-0101479.
PR 24-SEP-1998; 98US-0101738.
PR 24-SEP-1998; 98US-0101741.
PR 24-SEP-1998; 98US-0101743.
PR 24-SEP-1998; 98US-0101915.
PR 24-SEP-1998; 98US-0101916.
PR 29-SEP-1998; 98US-0102207.
PR 29-SEP-1998; 98US-0102240.
PR 29-SEP-1998; 98US-0102307.
PR 29-SEP-1998; 98US-0102330.
PR 29-SEP-1998; 98US-0102331.
PR 30-SEP-1998; 98US-0102484.
PR 30-SEP-1998; 98US-0102487.
PR 30-SEP-1998; 98US-0102570.
PR 30-SEP-1998; 98US-0102571.
PR 01-OCT-1998; 98US-0102684.
PR 01-OCT-1998; 98US-0102687.
PR 02-OCT-1998; 98US-0102965.
PR 06-OCT-1998; 98US-0103258.
PR 06-OCT-1998; 98US-0103449.
PR 07-OCT-1998; 98US-0103314.
PR 07-OCT-1998; 98US-0103315.
PR 07-OCT-1998; 98US-0103328.
PR 07-OCT-1998; 98US-0103395.
PR 07-OCT-1998; 98US-0103396.
PR 07-OCT-1998; 98US-0103401.
PR 08-OCT-1998; 98US-0103633.
PR 08-OCT-1998; 98US-0103678.
PR 08-OCT-1998; 98US-0103679.
PR 08-OCT-1998; 98US-0103711.
PR 14-OCT-1998; 98US-0104257.
PR 20-OCT-1998; 98US-0104987.
PR 20-OCT-1998; 98US-0105000.
PR 20-OCT-1998; 98US-0105002.
PR 21-OCT-1998; 98US-0105104.
PR 22-OCT-1998; 98US-0105169.
PR 22-OCT-1998; 98US-0105266.
PR 26-OCT-1998; 98US-0105693.
PR 26-OCT-1998; 98US-0105694.
PR 27-OCT-1998; 98US-0105807.
PR 27-OCT-1998; 98US-0105881.
PR 27-OCT-1998; 98US-0105882.
PR 27-OCT-1998; 98US-0106062.
PR 28-OCT-1998; 98US-0106023.
PR 28-OCT-1998; 98US-0106029.
PR 28-OCT-1998; 98US-0106030.
PR 28-OCT-1998; 98US-0106032.
PR 28-OCT-1998; 98US-0106033.
PR 28-OCT-1998; 98US-0106178.
PR 29-OCT-1998; 98US-0106248.
PR 29-OCT-1998; 98US-0106384.
PR 29-OCT-1998; 98US-0108500.
PR 30-OCT-1998; 98US-0106464.
PR 03-NOV-1998; 98US-0106856.
PR 03-NOV-1998; 98US-0106902.
PR 03-NOV-1998; 98US-0106905.
PR 03-NOV-1998; 98US-0106919.
PR 03-NOV-1998; 98US-0106932.
PR 03-NOV-1998; 98US-0106934.
PR 10-NOV-1998; 98US-0107783.
PR 17-NOV-1998; 98US-0108775.
PR 17-NOV-1998; 98US-0108779.
PR 17-NOV-1998; 98US-0108787.
PR 17-NOV-1998; 98US-0108788.
PR 17-NOV-1998; 98US-0108801.
PR 17-NOV-1998; 98US-0108802.
PR 17-NOV-1998; 98US-0108806.
PR 17-NOV-1998; 98US-0108807.
PR 17-NOV-1998; 98US-0108867.
PR 17-NOV-1998; 98US-0108925.
PR 18-NOV-1998; 98US-0108848.
PR 18-NOV-1998; 98US-0108849.
PR 18-NOV-1998; 98US-0108850.
PR 18-NOV-1998; 98US-0108851.
PR 18-NOV-1998; 98US-0108852.
PR 18-NOV-1998; 98US-0108858.
PR 18-NOV-1998; 98US-0108904.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
XX
DR WPI; 2000-237871/20.
DR N-PSDB; AAA37063.
XX
PT New mammalian DNA sequences encoding transmembrane, receptor or
PT secreted PRO polypeptides, useful for screening of potential peptide or
PT small molecule inhibitors of the relevant receptor/ligand interactions
XX
PS Claim 12; Fig 84; 773pp; English.
XX
CC AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The
CC transmembrane and receptor PRO proteins can be used for screening of
CC potential peptide or small molecule inhibitors of the relevant
CC receptor/ligand interactions. The polypeptides and nucleotide sequences
CC encoding then have various industrial applications, including uses as
CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent
CC PCR primers and hybridisation probes used in the isolation of the PRO
CC polypeptides from the present invention.
XX
SQ Sequence 311 AA;

Query Match 100.0%; Score 1651; DB 21; Length 311;
Best Local Similarity 100.0%; Pred. No. 1.1e-137;
Matches 311; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
Db 1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy 61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy         121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy         181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy         241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy         301 PVPDSPNFEVI 311
                ||||||||||||
Db         301 PVPDSPNFEVI 311


RESULT 2
AAB66130
ID   AAB66130 standard; protein; 311 AA.
XX
AC   AAB66130;
XX
DT   02-APR-2001  (first entry)
XX
DE   Protein of the invention #42.
XX
KW   Secreted; transmembrane; gene therapy.
XX
OS   Unidentified.
XX
PN   WO200078961-A1.
XX
PD   28-DEC-2000.
XX
PF   18-FEB-2000; 2000WO-US04342.
XX
PR   23-JUN-1999;   99US-0141037.
PR   20-JUL-1999;   99US-0144758.
PR   26-JUL-1999;   99US-0145698.
PR   01-SEP-1999;   99WO-US20111.
PR   29-OCT-1999;   99US-0162506.
PR   30-NOV-1999;   99WO-US28313.
PR   02-DEC-1999;   99WO-US28551.
PR   16-DEC-1999;   99WO-US30095.
PR   05-JAN-2000; 2000WO-US00219.
PR   06-JAN-2000; 2000WO-US00376.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI   Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
PI   Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D;
PI   Watanabe CK, Williams PM, Wood WI;
XX
DR   WPI; 2001-071395/08.
XX
PT   Secreted and transmembrane proteins and nucleic acids designated PRO,
PT   useful as hybridization probes, in chromosome and gene mapping and gene
PT   therapy -
XX
PS   Claim 1; Fig 84; 787pp; English.
XX
CC   The present invention relates to secreted and transmembrane proteins.
CC   These proteins and the DNA encoding them may be used as hybridization
CC   probes, in chromosome and gene mapping and in the generation of
CC   anti-sense RNA and DNA. They may also be used used to generate either
CC   transgenic animals or knockout animals which are in turn useful for
CC   development and screening of therapeutically useful reagents.
CC   The nucleic acids may also be used in gene therapy.
XX
SQ   Sequence   311 AA;

  Query Match             100.0%;  Score 1651;  DB 22;  Length 311;
  Best Local Similarity   100.0%;  Pred. No. 1.1e-137;
  Matches  311;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy          61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy         121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy         181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy         241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy         301 PVPDSPNFEVI 311
                ||||||||||||
Db         301 PVPDSPNFEVI 311


RESULT 3
ABB95521
ID   ABB95521 standard; Protein; 311 AA.
XX
AC   ABB95521;
XX
DT   19-JUL-2002  (first entry)
XX
DE   Human angiogenesis related protein PRO1412 SEQ ID NO: 198.
XX
KW   Human; angiogenesis; PRO protein; cardiovascularisation; wound; cancer;
KW   atherosclerosis; cardiac hypertrophy; gene therapy; endothelial disorder;
KW   cardiant; cytostatic; antiangiogenic; hypotensive; vulnerary;
KW   antiarteriosclerotic.
XX
OS   Homo sapiens.
XX
PN   WO200208284-A2.
XX
PD   31-JAN-2002.
XX
PF   09-JUL-2001; 2001WO-US21735.
XX
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220664P.
PR   28-JUL-2000; 2000WO-US20710.
PR   02-AUG-2000; 2000US-222695P.
PR   17-AUG-2000; 2000US-0643657.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   07-SEP-2000; 2000US-230978P.
PR   15-SEP-2000; 2000US-000000P.
PR   18-SEP-2000; 2000US-0664610.
PR   18-SEP-2000; 2000US-0665350.
PR   24-OCT-2000; 2000US-242922P.
PR   08-NOV-2000; 2000US-0709238.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
```

```
PR   20-DEC-2000; 2000WO-US34956.
PR   22-JAN-2001; 2001US-0767609.
PR   28-FEB-2001; 2001US-0796498.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
PR   25-MAY-2001; 2001US-0866028.
PR   25-MAY-2001; 2001US-0866034.
PR   25-MAY-2001; 2001WO-US17092.
PR   30-MAY-2001; 2001US-0870574.
PR   30-MAY-2001; 2001WO-US17443.
PR   01-JUN-2001; 2001WO-US17800.
PR   20-JUN-2001; 2001WO-US19692.
PR   28-JUN-2001; 2001WO-US00000.
XX
PA   (GETH ) GENENTECH INC.
PA   (BAKE/) BAKER K P.
PA   (FERR/) FERRARA N.
PA   (GERB/) GERBER H.
PA   (GERR/) GERRITSEN M E.
PA   (GODD/) GODDARD A.
PA   (GODO/) GODOWSKI P J.
PA   (GURN/) GURNEY A L.
PA   (HILL/) HILLAN K J.
PA   (MARS/) MARSTERS S A.
PA   (PANJ/) PAN J.
PA   (PAON/) PAONI N F.
PA   (STEP/) STEPHAN J F.
PA   (WATA/) WATANABE C K.
PA   (WILL/) WILLIAMS P M.
PA   (WOOD/) WOOD W I.
XX
PI   Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI   Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI   Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR   WPI; 2002-171999/22.
DR   N-PSDB; ABL95659.
XX
PT   One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT   useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT   infarction), endothelial or angiogenic disorders in a mammal -
XX
PS   Claim 11; Fig 198; 567pp; English.
XX
CC   The present invention provides the protein and coding sequences of human
CC   PRO proteins. These are useful for treating or diagnosing a
CC   cardiovascular, endothelial or angiogenic disorder, including cardiac
CC   hypertrophy, trauma, cancer, age-related macular degeneration,
CC   atherosclerosis, hypertension, arterial restenosis, rheumatoid arthritis,
CC   angina, myocardial infarctions, thrombophlebitis, lymphangitis, tumour
CC   angiogenesis (such as breast carcinoma and liver carcinoma) and wound
CC   healing. The present sequence is a PRO protein of the invention.
XX
SQ   Sequence   311 AA;

  Query Match             100.0%;  Score 1651;  DB 23;  Length 311;
  Best Local Similarity   100.0%;  Pred. No. 1.1e-137;
  Matches  311;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy        301 PVPDSPNFEVI 311
              |||||||||||
Db        301 PVPDSPNFEVI 311


RESULT 4
ABB84915
ID   ABB84915 standard; Protein; 311 AA.
XX
AC   ABB84915;
XX
DT   16-MAY-2002  (first entry)
XX
DE   Human PRO1412 protein sequence SEQ ID NO:198.
XX
KW   Human; angiogenesis; cardiant; cytostatic; antiangiogenic; hypotensive;
KW   vulnerary; antiarteriosclerotic; PRO agonist; PRO antagonist; trauma;
KW   gene therapy; cardiovascular disorder; endothelial disorder; cancer;
KW   angiogenic disorder; cardiac hypertrophy; atherosclerosis; hypertension;
KW   age-related macular degeneration; arterial restenosis; angina;
KW   rheumatoid arthritis; myocardial infarction; thrombophlebitis;
KW   lymphangitis; tumour angiogenesis; breast carcinoma; liver carcinoma;
KW   wound healing; chromosome mapping; gene mapping.
XX
OS   Homo sapiens.
XX
PN   WO200200690-A2.
XX
PD   03-JAN-2002.
XX
PF   20-JUN-2001; 2001WO-US19692.
XX
PR   23-JUN-2000; 2000US-213637P.
PR   20-JUL-2000; 2000US-219556P.
PR   25-JUL-2000; 2000US-220624P.
PR   25-JUL-2000; 2000US-220664P.
PR   28-JUL-2000; 2000WO-US20710.
PR   02-AUG-2000; 2000US-222695P.
PR   17-AUG-2000; 2000US-0643657.
PR   23-AUG-2000; 2000WO-US23522.
PR   24-AUG-2000; 2000WO-US23328.
PR   07-SEP-2000; 2000US-230978P.
PR   18-SEP-2000; 2000US-0664610.
PR   18-SEP-2000; 2000US-0665350.
PR   24-OCT-2000; 2000US-242922P.
PR   08-NOV-2000; 2000US-0709238.
PR   08-NOV-2000; 2000WO-US30952.
PR   10-NOV-2000; 2000WO-US30873.
PR   01-DEC-2000; 2000WO-US32678.
PR   20-DEC-2000; 2000US-0747259.
PR   20-DEC-2000; 2000WO-US34956.
PR   22-JAN-2001; 2001US-0767609.
PR   28-FEB-2001; 2001US-0796498.
PR   28-FEB-2001; 2001WO-US06520.
PR   01-MAR-2001; 2001WO-US06666.
PR   09-MAR-2001; 2001US-0802706.
PR   14-MAR-2001; 2001US-0808689.
PR   22-MAR-2001; 2001US-0816744.
PR   05-APR-2001; 2001US-0828366.
PR   10-MAY-2001; 2001US-0854208.
PR   10-MAY-2001; 2001US-0854280.
```

PR 25-MAY-2001; 2001US-0866028.
PR 25-MAY-2001; 2001US-0866034.
PR 25-MAY-2001; 2001WO-US17092.
PR 30-MAY-2001; 2001US-0870574.
PR 30-MAY-2001; 2001WO-US17443.
PR 01-JUN-2001; 2001WO-US17800.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Ferrara N, Gerber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Gurney AL, Hillan KJ, Marsters SA, Pan J, Paoni NF;
PI Stephan JF, Watanabe CK, Williams PM, Wood WI, Ye W;
XX
DR WPI; 2002-090516/12.
DR N-PSDB; ABL88170.
XX
PT One hundred and eighty seven nucleic acids encoding PRO polypeptides,
PT useful in diagnosis and treatment of cardiovascular (e.g. myocardial
PT infarction), endothelial or angiogenic disorders in a mammal -
XX
PS Claim 11; Fig 198; 565pp; English.
XX
CC ABL88072 to ABL88258 encode the PRO proteins given in ABB84817 to
CC ABB85003. The PRO proteins and polynucleotides have cardiant, cytostatic,
CC antiangiogenic, hypotensive, vulnerary and antiarteriosclerotic
CC activities, and can be used in gene therapy. The PRO polynucleotides,
CC proteins, agonists and antagonists are useful for treating or diagnosing
CC a cardiovascular, endothelial or angiogenic disorder in a mammal,
CC e.g. cardiac hypertrophy, trauma, cancer, age-related macular
CC degeneration, atherosclerosis, hypertension, arterial restenosis,
CC rheumatoid arthritis, angina, myocardial infarctions, thrombophlebitis,
CC lymphangitis, tumour angiogenesis (such as breast carcinoma and liver
CC carcinoma) and wound healing. The PRO polynucleotides have applications
CC in molecular biology, including use as hybridisation probes, and in
CC chromosome and gene mapping. ABL88259 to ABL88267 represent primers and
CC probes used in the exemplification of the present invention.
XX
SQ Sequence 311 AA;

Query Match 100.0%; Score 1651; DB 23; Length 311;
Best Local Similarity 100.0%; Pred. No. 1.1e-137;
Matches 311; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy        301 PVPDSPNFEVI 311
              |||||||||||
Db        301 PVPDSPNFEVI 311
```

RESULT 5
AAU83678
ID AAU83678 standard; Protein; 311 AA.
XX
AC AAU83678;
XX
DT 08-MAY-2002 (first entry)
XX
DE Human PRO protein, Seq ID No 174.
XX
KW Human; secreted protein; PRO; tumour; lung cancer; colon cancer;
KW breast cancer; prostate tumour; rectal tumour; liver tumour;
KW pericyte cell proliferation; chondrocyte cell proliferation;
KW tumour necrosis factor-alpha.
XX
OS Homo sapiens.
XX
PN WO200208288-A2.
XX
PD 31-JAN-2002.
XX
PF 29-JUN-2001; 2001WO-US21066.
XX
PR 20-JUL-2000; 2000US-219556P.
PR 25-JUL-2000; 2000US-220585P.
PR 25-JUL-2000; 2000US-220605P.
PR 25-JUL-2000; 2000US-220607P.
PR 25-JUL-2000; 2000US-220624P.
PR 25-JUL-2000; 2000US-220638P.
PR 25-JUL-2000; 2000US-220664P.
PR 25-JUL-2000; 2000US-220666P.
PR 26-JUL-2000; 2000US-220893P.
PR 28-JUL-2000; 2000WO-US20710.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 15-SEP-2000; 2000US-000000P.
PR 10-NOV-2000; 2000WO-US30873.
PR 28-NOV-2000; 2000US-253646P.
PR 01-DEC-2000; 2000WO-US32678.
PR 20-DEC-2000; 2000US-0747259.
PR 20-DEC-2000; 2000WO-US34956.
PR 28-FEB-2001; 2001WO-US06520.
PR 10-MAY-2001; 2001US-0854280.
PR 25-MAY-2001; 2001WO-US17092.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Desnoyers L, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Smith V, Stephan JF, Watanabe CK, Wood WI;
XX
DR WPI; 2002-172001/22.
DR N-PSDB; ABK33622.
XX
PT One hundred and twenty two nucleic acids encoding PRO polypeptides,
PT useful for treating a PRO related disorder and for diagnosing tumours
PT such as lung cancer, colon cancer, breast tumour, prostate tumour, rectal
PT tumour or liver tumour -
XX
PS Claim 11; Figure 174; 359pp; English.
XX
CC The invention relates to one hundred and twenty two nucleic acids
CC encoding PRO polypeptides. The sequences of the 122 PRO polynucleotides
CC encode human secreted proteins. The PRO nucleic acids, polypeptides,
CC agonists and antagonists are useful for treating a PRO related disorder.
CC The PRO polypeptides are useful for diagnosing tumours, especially lung
CC cancer, colon cancer, breast tumour, prostate tumour, rectal tumour or
CC liver tumour. The PRO polypeptides are useful for stimulating the
CC proliferation of, or gene expression, in pericyte cells, for stimulating
CC the proliferation or differentiation of chondrocyte cells, for
CC stimulating the release of tumour necrosis factor-alpha from human blood,
CC for stimulating or inhibiting the proliferation of normal human dermal
CC fibroblast cells. The PRO polypeptide may also be used as molecular
CC weight markers and for tissue typing. The PRO nucleic acids have
CC applications in molecular biology, including use as hybridisation probes,
CC and in chromosome and gene mapping. AAU83592-AAU83713 represent human PRO
CC protein sequences of the invention.
XX
SQ Sequence 311 AA;

```
  Query Match             100.0%;  Score 1651;  DB 23;  Length 311;
  Best Local Similarity   100.0%;  Pred. No. 1.1e-137;
  Matches  311;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy        301 PVPDSPNFEVI 311
              |||||||||||
Db        301 PVPDSPNFEVI 311
```

```
RESULT 6
AAB31676
ID   AAB31676 standard; Protein; 311 AA.
XX
AC   AAB31676;
XX
DT   30-APR-2001  (first entry)
XX
DE   Amino acid sequence of a human protein having a hydrophobic domain.
XX
KW   Human; hydrophobic protein; secretory protein; membrane protein; sepsis;
KW   tumour inhibition; immune deficiency; autoimmune disorder; anaemia; burn;
KW   infectious disease; cancer; ulcer; periodontal disease; coagulation;
KW   Parkinson's disease; fertility; immune response; thrombosis.
XX
OS   Homo sapiens.
XX
PN   WO200104297-A2.
XX
PD   18-JAN-2001.
XX
PF   16-JUN-2000; 2000WO-JP03942.
XX
PR   08-JUL-1999;   99JP-0194359.
XX
PA   (SAGA ) SAGAMI CHEM RES CENT.
PA   (PROT-) PROTEGENE INC.
XX
PI   Kato S,  Kimura T;
XX
DR   WPI; 2001-103081/11.
DR   N-PSDB; AAF25166, AAF25176.
XX
PT   Isolated human proteins and polynucleotides are used in research and
PT   have activities including cell proliferation/differentiation activity,
PT   immune stimulating activity and receptor/ligand activity -
XX
PS   Claim 1; Page 102-104; 151pp; English.
XX
CC   The present sequence represents a human protein with hydrophobic domains.
CC   The protein possesses a hydrophobic domain and so is a secretory protein
CC   or a membrane protein. The protein is used as an antigen to prepare
CC   antibodies. The polynucleotide sequence is useful as a source of probes
CC   for genetic diagnosis. It is also useful for producing the protein
CC   in large quantities and for gene therapy. The eukaryotic cells are used
CC   for detecting the receptors or ligands corresponding to the protein and
CC   for detecting small novel pharmaceuticals. The antibodies are also used
CC   for detection, quantification and purification of the proteins. Both the
CC   protein and polynucleotide may be used in research or as nutritional
CC   sources or supplements. The protein may have cytokine and cell
CC   proliferation/differentiation activity, immune stimulating or suppressing
CC   activity, hematopoiesis regulating activity, tissue growth activity,
CC   activin/inhibin activity, chemotactic/chemokinetic activity, hemostatic
CC   and thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC   activity and tumour inhibition activity. It may therefore may be used to
CC   treat immune deficiencies resulting from autoimmune disorders or
CC   infectious diseases, cancer, sepsis, anaemias, burns and ulcers,
CC   periodontal disease, Parkinson's disease, induce fertility, improve
CC   immune response and enhance coagulation or inhibit thrombosis.
XX
SQ   Sequence   311 AA;
```

```
  Query Match             99.8%;  Score 1647;  DB 22;  Length 311;
  Best Local Similarity   99.7%;  Pred. No. 2.5e-137;
  Matches  310;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
              |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 YPSSSQESENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy        301 PVPDSPNFEVI 311
              |||||||||||
Db        301 PVPDSPNFEVI 311
```

```
RESULT 7
AAY87247
ID   AAY87247 standard; Protein; 311 AA.
XX
AC   AAY87247;
XX
DT   11-MAY-2000  (first entry)
XX
DE   Human signal peptide containing protein HSPP-24 SEQ ID NO:24.
XX
KW   Human; signal peptide-containing protein; HSPP; diagnosis; cancer;
KW   inflammation; cardiovascular disease; anticancer; anti-inflammatory;
KW   antimicrobial; nootropic; neuroprotective; cardiovascular; hepatotropic;
KW   antiasthmatic; gene therapy; cell proliferation; neurological disorder;
KW   reproductive disorder; developmental disorder; arteriosclerosis;
KW   cirrhosis; psoriasis; acquired immune deficiency syndrome; anaemia;
KW   asthma; Crohn's disease; infection; Alzheimer's disease; schizophrenia;
KW   Parkinson's disease; Huntington's diseases; ovulatory defect;
KW   muscular dystrophy.
XX
OS   Homo sapiens.
XX
PN   WO200000610-A2.
XX
PD   06-JAN-2000.
```

```
XX
PF   25-JUN-1999;   99WO-US14484.
XX
PR   26-JUN-1998;   98US-0090762.
PR   31-JUL-1998;   98US-0094983.
PR   01-OCT-1998;   98US-0102686.
PR   11-DEC-1998;   98US-0112129.
XX
PA   (INCY-) INCYTE PHARM INC.
XX
PI   Lal P,  Tang YT,  Gorgone GA,  Corley NC,  Guegler KJ,  Baughn MR;
PI   Akerblom IE,  Au-Young J,  Yue H,  Patterson C,  Reddy R,  Hillman JL;
PI   Bandman O;
XX
DR   WPI; 2000-160673/14.
DR   N-PSDB; AAZ98132.
XX
PT   New human signal peptide-containing proteins useful in treatment,
PT   prevention and diagnosis of e.g. cancer, inflammation and
PT   cardiovascular disease  -
XX
PS   Claim 1; Page 175; 327pp; English.
XX
CC   AAZ98109 to AAZ98242 encode AAY87224 to AAY87357 which represent the
CC   human signal peptide-containing proteins HSPP-1 to HSPP-134. HSPPs have
CC   anticancer, anti-inflammatory, antimicrobial, nootropic, hepatotropic,
CC   neuroprotective, cardiovascular and antiasthmatic activities, and can
CC   be used in gene therapy. HSPPs can be used to treat or prevent disorders
CC   associated with decreased activity or function of HSPP. Antagonists of
CC   HSPP are used to treat or prevent disorders associated with increased
CC   activity or function of HSPP. Such diseases include cell proliferation
CC   (including cancer), inflammation, cardiovascular, neurological,
CC   reproductive or developmental disorders, (e.g. arteriosclerosis,
CC   cirrhosis, psoriasis, acquired immune deficiency syndrome, anaemia,
CC   asthma, Crohn's disease, microbial or other infections, congestive or
CC   ischaemic heart disease, Alzheimer's, Parkinson's or Huntington's
CC   diseases, schizophrenia, ovulatory defects, muscular dystrophy). HSPP
CC   nucleic acids can be used for the recombinant production of HSPP, for
CC   detecting HSPP in standard hybridisation and amplification assays (for
CC   diagnosis and monitoring), in gene therapy, as antisense,
CC   triplex-forming or ribozyme therapeutics, for detecting related sequences
CC   or genetic variations, and for chromosomal mapping. HSPP are also used to
CC   raise specific antibodies (Ab) and to screen for agonists and
CC   antagonists (potential therapeutic agents). Ab are used to diagnose, or
CC   monitor, HSPP-related diseases (in usual immunoassays), as therapeutic
CC   antagonists, in competitive drug screens, and for purification of HSPP
CC   from natural sources.
XX
SQ   Sequence   311 AA;

  Query Match             99.3%;  Score 1640;  DB 21;  Length 311;
  Best Local Similarity   99.4%;  Pred. No. 1.1e-136;
  Matches  309;  Conservative    1;  Mismatches    1;  Indels    0;  Gaps    0;

Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
              |||||| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGVPTAPEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Qy        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180

Qy        181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
              ||||||:||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        181 YPSSSQESENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240

Qy        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300

Qy        301 PVPDSPNFEVI 311
              |||||||||||
Db        301 PVPDSPNFEVI 311


RESULT 8
ABG70193
ID   ABG70193 standard; Protein; 193 AA.
XX
AC   ABG70193;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Human prey protein for Shigella ipaH9.8 #23.
XX
KW   Prey protein; ospB; ospD1; ipaD; ipaC; ipaH9.8; ospG;
KW   ospC1; Shigella; shigellosis; bacillary dysentery; antibacterial;
KW   yeast two-hybrid system; protein-protein interaction; SID;
KW   selected interacting domain; human.
XX
OS   Homo sapiens.
XX
PN   WO200257303-A2.
XX
PD   25-JUL-2002.
XX
PF   11-JAN-2002; 2002WO-EP00777.
XX
PR   12-JAN-2001; 2001US-261130P.
XX
PA   (HYBR-) HYBRIGENICS.
XX
PI   Legrain P;
XX
DR   WPI; 2002-599706/64.
DR   N-PSDB; ABS51586.
XX
PT   New complex of protein-protein interactions between a bait Shigella
PT   flexneri polypeptide and a prey mammalian or human placenta polypeptide
PT   for treating or preventing bacillary dysentery in a mammal or human  -
XX
PS   Claim 7; Page 124; 162pp; English.
XX
CC   The invention relates to a complex of protein-protein interactions
CC   between a Shigella flexneri polypeptide (e.g. ospB, ospD1, ipaD, ipaC,
CC   ipaH9.8, ospG and ospC1) and a mammalian polypeptide defined in the
CC   specification. The complexes are formed using the yeast two-hybrid
CC   system. Also included are (1) a recombinant host cell expressing the
CC   interactions between the Shigella flexneri polypeptide and a mammalian
CC   polypeptide defined in the specification; (2) selecting a modulating
CC   compound that inhibits or activates the protein-protein interactions;
CC   (3) a modulating compound obtained from the method of (2); (4) a SID
CC   (selected interacting domain) polypeptide or its fragment or variant
CC   comprising the human polypeptides appearing as ABG70042-ABG70242;
CC   (5) a SID polynucleotide or its fragment or variant comprising
CC   encoding the above polypeptides a vector comprising (5);
CC   (6) a recombinant host cell containing the vector; and (10) a protein
CC   chip comprising Shigella flexneri polypeptide and a mammalian polypeptide
CC   defined in the specification. A pharmaceutical composition comprising the
CC   compound, polypeptide or polynucleotide is useful for treating or
CC   preventing shigellosis (bacillary dysentery) in a human or mammal.
CC   The present sequence represents a human prey protein isolated by the
CC   yeast two-hybrid assay, forming a complex of the invention with a
CC   shigella protein.
XX
SQ   Sequence   193 AA;

  Query Match             62.4%;  Score 1030;  DB 23;  Length 193;
  Best Local Similarity   100.0%;  Pred. No. 5.1e-83;
  Matches  193;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         31 AAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIR 90
```

```
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 AAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERRPIR 60

Qy         91 NLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVE 150
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 NLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCLVVE 120

Qy        151 IRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPL 210
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 IRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENITAAALATGACIVGILCLPL 180

Qy        211 ILLLVYKQRQAAS 223
                 |||||||||||||
Db        181 ILLLVYKQRQAAS 193


RESULT 9
ABU11286
ID   ABU11286 standard; Protein; 179 AA.
XX
AC   ABU11286;
XX
DT   10-FEB-2003  (first entry)
XX
DE   cDNA encoding human cancer suppressing protein PP7827.
XX
KW   Human; cancer suppressing protein; cancer.
XX
OS   Homo sapiens.
XX
PN   CN1351081-A.
XX
PD   29-MAY-2002.
XX
PF   31-OCT-2000; 2000CN-0127102.
XX
PR   31-OCT-2000; 2000CN-0127102.
XX
PA   (SHAN-) SHANGHAI INST ONCOLOGY.
XX
PI   Gu J;
XX
DR   WPI; 2002-609437/66.
DR   N-PSDB; ABX34032.
XX
PT   New human protein with cancer cell growth suppressing function and a
PT   polynucleotide encoding it, for treating diseases, such as, cancer -
XX
PS   Claim 1; Page 31 (disclosure); 39pp; Chinese.
XX
CC   This invention relates to the cDNA and protein sequences of a novel
CC   human protein with cancer suppressing function. The invention also
CC   comprises a method for preparing the polypeptide by recombination,
CC   and an application of the polypeptide in treating diseases such as
CC   cancer, etc. Also disclosed in an antagonist of the polypeptide and
CC   its medical action. The present sequence represents a cancer
CC   suppressing protein of the invention.
XX
SQ   Sequence   179 AA;

  Query Match           56.4%;  Score 931;  DB 23;  Length 179;
  Best Local Similarity   99.4%;  Pred. No. 2.7e-74;
  Matches  178;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy        133 MRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSENIT 192
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||:|||||
Db          1 MRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQESENIT 60

Qy        193 AAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQ 252
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 AAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQ 120

Qy        253 GIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI 311
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db        121 GIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI 179


RESULT 10
ABG03875
ID   ABG03875 standard; Protein; 1509 AA.
XX
AC   ABG03875;
XX
DT   13-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #3866.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT,  Liu C,  Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS68062.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity  -
XX
PS   Claim 20; SEQ ID No 34234; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG30377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   1509 AA;

  Query Match           53.8%;  Score 889;  DB 22;  Length 1509;
  Best Local Similarity   66.2%;  Pred. No. 2.4e-69;
  Matches  184;  Conservative   14;  Mismatches   38;  Indels   42;  Gaps    5;

Qy         28 GPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERR 87
                 ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         23 GPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPVDKGHDVTFYKTWYRSSRGEVQTCSERR 82
```

```
Qy          88 PIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCL 147
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          83 PIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLESASDHHGNFSITMRNLTLLDSGLYCCL 142

Qy         148 VVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSE----NITAAALATGACIV 203
               ||||||||||||||||||||||||||||||||||||||||||    |     :: |  :
Db         143 VVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVVYPSSSQDSESNHGNNFRIHVSNGLLMR 202

Qy         204 GILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPL 263
               |                    |  :  |  |::  :|   :  |   :   |:|
Db         203 G--------------------PRPLDRERNSSHVLIVEAYNHDLGPMRSSVRMRKLRQST 242

Qy         264 SYVAQ--------------RQPSESGRHLLSEPSTPL 286
               : :||              |:|| |  ||||:  | |
Db         243 A-LAQHWTGTALDRKQVWFSRKPSCS--HLLSKNLTDL 277
```

RESULT 11
AAB88583
ID AAB88583 standard; Protein; 168 AA.
XX
AC AAB88583;
XX
DT 04-JUN-2001 (first entry)
XX
DE Human hydrophobic domain containing protein clone HP10727 #67.
XX
KW Human; hydrophobic domain; immunosuppressant; anti-HIV; neuroprotective;
KW antianaemic; vulnerary; antiulcer; osteopathic; anti-inflammatory;
KW cytostatic; gene therapy; autoimmune disorder; multiple sclerosis;
KW HIV infection; anaemia; burn; ulcer; osteoporosis; tumour; wound healing;
KW inflammatory bowel disease; nutritional supplement; appetite; vaccine;
KW behavioural characteristic; immune response.
XX
OS Homo sapiens.
XX
PN WO200112660-A2.
XX
PD 22-FEB-2001.
XX
PF 10-AUG-2000; 2000WO-JP05356.
XX
PR 17-AUG-1999; 99JP-0230344.
PR 07-SEP-1999; 99JP-0252551.
PR 01-OCT-1999; 99JP-0281132.
PR 22-OCT-1999; 99JP-0301624.
PR 04-NOV-1999; 99JP-0313877.
XX
PA (SAGA) SAGAMI CHEM RES CENT.
PA (PROT-) PROTEGENE INC.
XX
PI Kato S, Kimura T;
XX
DR WPI; 2001-160059/16.
DR N-PSDB; AAF94463.
XX
PT Human proteins with hydrophobic domains and the DNAs which encode them
PT are useful for treating autoimmune disorders, burns and tumors and for
PT screening novel pharmaceuticals -
XX
PS Claim 1; Page 358-359; 518pp; English.
XX
CC AAF94417 to AAF94516 encode the human proteins given in AAB88557 to
CC AAB88606 (I) which have a hydrophobic domain. (I) have immunosuppressant,
CC anti-HIV, neuroprotective, antianaemic, vulnerary, antiulcer,
CC osteopathic, anti-inflammatory and cytostatic activities, and can be
CC used in gene therapy. (I) can be used as pharmaceuticals and as antigens
CC to prepare antibodies. DNA and cDNA (II) encoding (I) can be used as
CC probes for genetic diagnosis and gene sources for gene therapy or for
CC producing (I) in large quantities. Cells containing (II) are used for
CC the detection of ligands or receptors corresponding to membrane or
CC secretory proteins and to screen small molecule novel pharmaceuticals.
CC Antibodies directed to (I) can be used for the detection, quantification
CC and purification of (I). Activities of (I) may include cytokine and cell
CC proliferation/differentiation function, immune stimulating or suppressing
CC activity, haematopoiesis regulating activity, tissue growth activity,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, receptor/ligand activity and anti-inflammatory
CC activity. (I) and (II) can be used to treat autoimmune disorders e.g.
CC multiple sclerosis, HIV infections, anaemia, burns, ulcers, osteoporosis,
CC inflammatory bowel disease and tumours. (I) and (II) can also be used for
CC wound healing, as nutritional sources or supplements e.g. as amino acid,
CC carbon or nitrogen source, to effect metabolism, catabolism, anabolism,
CC processing and utilisation of dietary fat, protein, carbohydrate,
CC vitamins and minerals, to effect behavioural characteristics, to affect
CC appetite, and can act as antigens in vaccines to raise an immune response
CC to the protein or another material cross-reactive with the protein.
XX
SQ Sequence 168 AA;

Query Match 47.5%; Score 783.5; DB 22; Length 168;
Best Local Similarity 53.7%; Pred. No. 2.7e-61;
Matches 167; Conservative 1; Mismatches 0; Indels 143; Gaps 1;

```
Qy           1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
               ||||||||||||||||||||||||||
Db           1 MGVPTALRAGSWRWGSLLFALFLAASL------------------------------- 27

Qy          61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTSHDLAQRHGLE 120

Db          28 ------------------------------------------------------------ 27

Qy         121 SASDHHGNFSITMRNLTLLDSGLYCCLVVEIRHHHSEHRVHGAMELQVQTGKDAPSNCVV 180
                                                                ||||||||||
Db          28 ----------------------------------------------------GKDAPSNCVV 37

Qy         181 YPSSSQDSENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 240
               ||||||:||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          38 YPSSSQESENITAAALATGACIVGILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGI 97

Qy         241 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 300
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          98 ENPGFEASPPAQGIPEAKVRHPLSYVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLD 157

Qy         301 PVPDSPNFEVI 311
               ||||||||||
Db         158 PVPDSPNFEVI 168
```

RESULT 12
AAB40620
ID AAB40620 standard; Protein; 110 AA.
XX
AC AAB40620;
XX
DT 08-FEB-2001 (first entry)
XX
DE Human ORFX ORF384 polypeptide sequence SEQ ID NO:768.
XX
KW Human; open reading frame; ORFX; detection; cytostatic; hepatotropic;
KW vulnerary; antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
KW anticonvulsant; osteopathic; antiarthritic; immunosuppressant; cardiant;
KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
KW hypotensive; dermatological; immunosuppressive; antiinflammatory;
KW antiviral; antibacterial; antifungal; antirheumatic; antithyroid;
KW antianaemic; gene therapy; cancer; proliferative disorder; hypertension;
KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
KW cholesterol ester storage; systemic lupus erythematosus; infection;
KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
KW bone damage; cartilage damage; antiinflammatory disease; coagulation;
KW thrombosis; contraceptive.
XX
OS Homo sapiens.

WO 00/58473
60/127607 - 3/31/99
127638
127728
09/540703

XX
PN WO200058473-A2.
XX
PD 05-OCT-2000.
XX
PF 31-MAR-2000; 2000WO-US08621.
XX
PR 31-MAR-1999; 99US-0127607.
PR 02-APR-1999; 99US-0127636.
PR 05-APR-1999; 99US-0127728.
PR 30-MAR-2000; 2000US-0540763.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Leach M;
XX
DR WPI; 2000-602362/57.
DR N-PSDB; AAC74829.
XX
PT Novel nucleic acids and peptides derived from open reading frame X,
PT useful for treating e.g. cancers, proliferative disorders,
PT neurodegenerative disorders and cardiovascular disease -
XX
PS Claim 11; Page 839; 5507pp; English.
XX
CC AAC74446 to AAC77606 encode the proteins given in AAB40237 to AAB43397,
CC which represent the human ORFX open reading frames 1 to 3161. The ORFX
CC sequences have activities such as: cytostatic; hepatotropic; vulnerary;
CC antipsoriatic; antiparkinsonian; nootropic; neuroprotective;
CC osteopathic; anticonvulsant; antiarthritic; immunosuppressant;
CC immunostimulant; cardiant; thrombolytic; coagulant; vasotropic;
CC antidiabetic; hypotensive; dermatological; immunosuppressive;
CC antiinflammatory; antibacterial; antiviral; antifungal; antirheumatic;
CC antithyroid; and antianaemic. The sequences can be used for determining
CC the presence of or predisposition to, or preventing or treating
CC pathological conditions associated with an ORFX-associated disorder. The
CC nucleic acids can be used to express ORFX proteins in gene therapy
CC vectors. The proteins and nucleic acids may be used to treat cancers,
CC proliferative disorders, neurodegenerative disorders, osteoarthritis,
CC graft vs host disease, cardiovascular disease, diabetes mellitus,
CC hypertension, hypothyroidism, cholesterol ester storage, systemic lupus
CC erythematosus, severe combined immunodeficiency (SCID), AIDS, viral,
CC bacterial or fungal infection, malaria, autoimmune disorders, asthma,
CC allergies, aplastic anaemia, burns, wounds, bone and cartilage damage,
CC nocturnal haemoglobinuria, antiinflammatory disease; to enhance
CC coagulation; to inhibit thrombosis; and as a contraceptive.
XX
SQ Sequence 110 AA;

Query Match 35.7%; Score 589; DB 21; Length 110;
Best Local Similarity 99.1%; Pred. No. 2.5e-44;
Matches 109; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60
              |||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MGVPTAPEAGSWRWGSLLFALFLAASLGPVAAFKVATPYSLYVCPEGQNVTLTCRLLGPV 60

Qy         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTS 110
              ||||||||||||||||||||||||||||||||||||||||||||||||||
Db         61 DKGHDVTFYKTWYRSSRGEVQTCSERRPIRNLTFQDLHLHHGGHQAANTS 110
```

RESULT 13
AAY36634
ID AAY36634 standard; Protein; 177 AA.
XX
AC AAY36634;
XX
DT 17-SEP-1999 (first entry)
XX
DE Fragment of human secreted protein encoded by gene 49.
XX
KW Human; secreted protein; cancer; tumour; developmental abnormality;
KW foetal deficiency; blood disorder; immune system disorder; inflammation;
KW autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW digestive disorder; endocrine disorder; infection; AIDS.
XX
OS Homo sapiens.
XX
PN WO9931117-A1.
XX
PD 24-JUN-1999.
XX
PF 17-DEC-1998; 98WO-US27059.
XX
PR 19-DEC-1997; 97US-0068369.
PR 18-DEC-1997; 97US-0068006.
PR 18-DEC-1997; 97US-0068007.
PR 18-DEC-1997; 97US-0068008.
PR 18-DEC-1997; 97US-0068053.
PR 18-DEC-1997; 97US-0068054.
PR 18-DEC-1997; 97US-0068057.
PR 18-DEC-1997; 97US-0068064.
PR 18-DEC-1997; 97US-0070923.
PR 19-DEC-1997; 97US-0068169.
PR 19-DEC-1997; 97US-0068365.
PR 19-DEC-1997; 97US-0068367.
PR 19-DEC-1997; 97US-0068368.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Carter KC, Duan RD, Feng P, Ferrie AM, Florence C;
PI Florence K, Greene JM, Janat F, Kyaw H, Moore PA;
PI Ni J, Rosen CA, Ruben SM, Shi Y, Soppet DR, Wei Y;
PI Yu G;
XX
DR WPI; 1999-418749/35.
XX
PT New isolated human genes encoding secreted polypeptides
XX
PS Disclosure; Page 506; 537pp; English.
XX
CC AAX97916 to AAX98029 represent 110 isolated human secreted protein
CC genes. AAY36224 to AAY36727 represent the secreted proteins encoded by
CC the 110 human genes. The genes and their corresponding secreted
CC polypeptides are useful for preventing, treating or ameliorating medical
CC conditions, e.g. by protein or gene therapy. Also pathological conditions
CC can be diagnosed by determining the amount of the new polypeptides in a
CC sample or by determining the presence of mutations in the new genes.
CC Specific uses are described for each of the 110 genes, based on which
CC tissues they are most highly expressed in, and include developing
CC products for the diagnosis or treatment of cancer, tumours, developmental
CC abnormalities and foetal deficiencies, blood disorders, diseases of the
CC immune system, autoimmune diseases, inflammation, allergies, Alzheimer's
CC and cognitive disorders, schizophrenia, arthritis, asthma, psoriasis,
CC sepsis, skin disorders, atherosclerosis, diabetes, cardiovascular
CC disorders, kidney disorders, digestive/endocrine disorders, infections
CC and AIDS. The polypeptides are also useful for identifying their binding
CC partners. The sequences given in AAX97907 to AAX97915 and AAY36223 are
CC used in the exemplification of the present invention.
XX
SQ Sequence 177 AA;

Query Match 33.7%; Score 556; DB 20; Length 177;
Best Local Similarity 100.0%; Pred. No. 3.9e-41;
Matches 107; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy        205 ILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLS 264
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db         53 ILCLPLILLLVYKQRQAASNRRAQELVRMDSNIQGIENPGFEASPPAQGIPEAKVRHPLS 112

Qy        265 YVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI 311
              |||||||||||||||||||||||||||||||||||||||||||||||
Db        113 YVAQRQPSESGRHLLSEPSTPLSPPGPGDVFFPSLDPVPDSPNFEVI 159
```

```
RESULT 14
AAY36272
ID   AAY36272 standard; Protein; 174 AA.
XX
AC   AAY36272;
XX
DT   17-SEP-1999  (first entry)
XX
DE   Human secreted protein encoded by gene 49.
XX
KW   Human; secreted protein; cancer; tumour; developmental abnormality;
KW   foetal deficiency; blood disorder; immune system disorder; inflammation;
KW   autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW   schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW   atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW   digestive disorder; endocrine disorder; infection; AIDS.
XX
OS   Homo sapiens.
XX
PN   WO9931117-A1.
XX
PD   24-JUN-1999.
XX
PF   17-DEC-1998;   98WO-US27059.
XX
PR   19-DEC-1997;   97US-0068369.
PR   18-DEC-1997;   97US-0068006.
PR   18-DEC-1997;   97US-0068007.
PR   18-DEC-1997;   97US-0068008.
PR   18-DEC-1997;   97US-0068053.
PR   18-DEC-1997;   97US-0068054.
PR   18-DEC-1997;   97US-0068057.
PR   18-DEC-1997;   97US-0068064.
PR   18-DEC-1997;   97US-0070923.
PR   19-DEC-1997;   97US-0068169.
PR   19-DEC-1997;   97US-0068365.
PR   19-DEC-1997;   97US-0068367.
PR   19-DEC-1997;   97US-0068368.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Carter KC,  Duan RD,  Feng P,  Ferrie AM,  Florence C;
PI   Florence K,  Greene JM,  Janat F,  Kyaw H,  Moore PA;
PI   Ni J,  Rosen CA,  Ruben SM,  Shi Y,  Soppet DR,  Wei Y;
PI   Yu G;
XX
DR   WPI; 1999-418749/35.
DR   N-PSDB; AAX97964.
XX
PT   New isolated human genes encoding secreted polypeptides
XX
PS   Claim 11; Page 372; 537pp; English.
XX
CC   AAX97916 to AAX98029 represent 110 isolated human secreted protein
CC   genes. AAY36224 to AAY36727 represent the secreted proteins encoded by
CC   the 110 human genes. The genes and their corresponding secreted
CC   polypeptides are useful for preventing, treating or ameliorating medical
CC   conditions, e.g. by protein or gene therapy. Also pathological conditions
CC   can be diagnosed by determining the amount of the new polypeptides in a
CC   sample or by determining the presence of mutations in the new genes.
CC   Specific uses are described for each of the 110 genes, based on which
CC   tissues they are most highly expressed in, and include developing
CC   products for the diagnosis or treatment of cancer, tumours, developmental
CC   abnormalities and foetal deficiencies, blood disorders, diseases of the
CC   immune system, autoimmune diseases, inflammation, allergies, Alzheimer's
CC   and cognitive disorders, schizophrenia, arthritis, asthma, psoriasis,
CC   sepsis, skin disorders, atherosclerosis, diabetes, cardiovascular
CC   disorders, kidney disorders, digestive/endocrine disorders, infections
CC   and AIDS. The polypeptides are also useful for identifying their binding
CC   partners. The sequences given in AAX97907 to AAX97915 and AAY36223 are
CC   used in the exemplification of the present invention.
XX
SQ   Sequence   174 AA;

  Query Match              8.2%;  Score 136;  DB 20;  Length 174;
  Best Local Similarity   87.5%;  Pred. No. 0.00055;
  Matches   28;  Conservative    0;  Mismatches    4;  Indels    0;  Gaps    0;

Qy          1 MGVPTALEAGSWRWGSLLFALFLAASLGPVAA 32
              |||||| ||||||||||||||||||    ||
Db          1 MGVPTAPEAGSWRWGSLLFALFLAASLDITAA 32


RESULT 15
AAY36636
ID   AAY36636 standard; Protein; 25 AA.
XX
AC   AAY36636;
XX
DT   17-SEP-1999  (first entry)
XX
DE   Fragment of human secreted protein encoded by gene 49.
XX
KW   Human; secreted protein; cancer; tumour; developmental abnormality;
KW   foetal deficiency; blood disorder; immune system disorder; inflammation;
KW   autoimmune disease; allergy; Alzheimer's disease; cognitive disorder;
KW   schizophrenia; arthritis; asthma; psoriasis; sepsis; skin disorder;
KW   atherosclerosis; diabetes; cardiovascular disorder; kidney disorder;
KW   digestive disorder; endocrine disorder; infection; AIDS.
XX
OS   Homo sapiens.
XX
PN   WO9931117-A1.
XX
PD   24-JUN-1999.
XX
PF   17-DEC-1998;   98WO-US27059.
XX
PR   19-DEC-1997;   97US-0068369.
PR   18-DEC-1997;   97US-0068006.
PR   18-DEC-1997;   97US-0068007.
PR   18-DEC-1997;   97US-0068008.
PR   18-DEC-1997;   97US-0068053.
PR   18-DEC-1997;   97US-0068054.
PR   18-DEC-1997;   97US-0068057.
PR   18-DEC-1997;   97US-0068064.
PR   18-DEC-1997;   97US-0070923.
PR   19-DEC-1997;   97US-0068169.
PR   19-DEC-1997;   97US-0068365.
PR   19-DEC-1997;   97US-0068367.
PR   19-DEC-1997;   97US-0068368.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Carter KC,  Duan RD,  Feng P,  Ferrie AM,  Florence C;
PI   Florence K,  Greene JM,  Janat F,  Kyaw H,  Moore PA;
PI   Ni J,  Rosen CA,  Ruben SM,  Shi Y,  Soppet DR,  Wei Y;
PI   Yu G;
XX
DR   WPI; 1999-418749/35.
XX
PT   New isolated human genes encoding secreted polypeptides
XX
PS   Disclosure; Page 507; 537pp; English.
XX
CC   AAX97916 to AAX98029 represent 110 isolated human secreted protein
CC   genes. AAY36224 to AAY36727 represent the secreted proteins encoded by
CC   the 110 human genes. The genes and their corresponding secreted
CC   polypeptides are useful for preventing, treating or ameliorating medical
CC   conditions, e.g. by protein or gene therapy. Also pathological conditions
CC   can be diagnosed by determining the amount of the new polypeptides in a
CC   sample or by determining the presence of mutations in the new genes.
CC   Specific uses are described for each of the 110 genes, based on which
CC   tissues they are most highly expressed in, and include developing
```

CC products for the diagnosis or treatment of cancer, tumours, developmental
CC abnormalities and foetal deficiencies, blood disorders, diseases of the
CC immune system, autoimmune diseases, inflammation, allergies, Alzheimer's
CC and cognitive disorders, schizophrenia, arthritis, asthma, psoriasis,
CC sepsis, skin disorders, atherosclerosis, diabetes, cardiovascular
CC disorders, kidney disorders, digestive/endocrine disorders, infections
CC and AIDS. The polypeptides are also useful for identifying their binding
CC partners. The sequences given in AAX97907 to AAX97915 and AAY36223 are
CC used in the exemplification of the present invention.
XX
SQ Sequence 25 AA;

Query Match 7.9%; Score 130; DB 20; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.00014;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 245 FEASPPAQGIPEAKVRHPLSYVAQR 269
||||||||||||||||||||||||||
Db 1 FEASPPAQGIPEAKVRHPLSYVAQR 25

Search completed: January 9, 2004, 00:41:48
Job time : 73 secs